

L5 ANSWER 1 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2008:317784 CAPLUS Full-text
 DN 148:315371
 TI Oral liquid pharmaceuticals containing CGRP antagonist trifluoroethyl
 pyridine
 IN Breslin, David; Stellabott, Joyce; Jahansouz, Hossain; Alani, Laman L.;
 Thompson, Karen
 PA Merck & Co., Inc., USA
 SO PCT Int. Appl., 23pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008030524	A2	20080313	WO 2007-US19461	20070906
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRAI US 2006-843052P P 20060908


AB Liquid formulations comprising the compound 1-[1-({[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]amino}carbonyl)piperidin-4-yl]-2-oxo-1,2-dihydroimidazo[4,5-b]pyridin-3-ide have surprisingly improved bioavailability and stability in comprising polyethylene glycol, Tween (polysorbate 80), Cremophor EL (polyoxyl 35 castor oil), propylene glycol, and optionally water, and may be filled into soft or hard gelatin capsules useful for treating conditions including migraine headache and cluster headache.

IT 781649-09-0
 RL: PKT (Pharmacokinetics); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (oral liquid pharmaceuticals containing CGRP antagonist trifluoroethyl pyridine)

RN 781649-09-0 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-2-oxo-1-(2,2,2-trifluoroethyl)-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 2 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2007:1274984 CAPLUS Full-text
 DN 147:522239
 TI Preparation of indazole compounds as CGRP-receptor antagonists
 IN Chaturvedula, Prasad V.; Mercer, Stephen E.; Fang, Haiquan; Han, Xiaojun;
 Luo, Guanglin; Dubowchik, Gene M.; Poindexter, Graham S.
 PA Bristol-Myers Squibb Company, USA
 SO U.S. Pat. Appl. Publ., 149pp.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2007259851	A1	20071108	US 2007-742626	20070501
	WO 2007131020	A2	20071115	WO 2007-US67998	20070502
	WO 2007131020	A3	20080117		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
PRAI	US 2006-797400P	P	20060503		
	US 2007-742626	A	20070501		
OS	MARPAT 147:522239				
GI					

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Bicyclic and tricyclic indazole compds. I, wherein A is O or NR1 provided that when A is NR1 then R1 is not H; R1 is C1-6-alkyl, C2-6-alkenyl, C3-7-cycloalkyl, C5-7-cyclo-alkenyl, C1-6-(C3-7-cycloalkyl)alkyl, C1-6-haloalkyl, C1-6-(C1-6-alkoxy)alkyl, C1-6-(Ar)alkyl, C1-6-(NR7R8)alkyl, N-(R9)-pyrrolidinyl or N-(R9)-piperidinyl; R2 is H, halo, or C1-6-alkyl; R3 is H, C1-6-alkyl, or C2-6-alkenyl; R4 is H, halo or C1-6-alkyl, or C2-6-alkenyl; R5 is H or C1-6-alkyl; R6 is H, C1-6-alkyl, heterocyclyl; R7 is hydrogen or C1-6-alkyl; R8 is hydrogen or C1-6-alkyl; or NR7R8 taken together is selected from the group consisting of pyrrolidinyl, piperidinyl, N-(R9)-piperazinyl, morpholinyl, and thio-morpholinyl; R9 is hydrogen, C1-6-alkyl, C1-6-alkylcarbonyl, or C1-6-alkoxycarbonyl; were prepared as CGRP-receptor antagonists, and may be used in therapy for treatment of migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors. Thus, title II was prepared and tested in vitro as human CGRP-receptor antagonist (IC50 = 0.1-10 nM).

IT 885606-79-1P 885606-81-5P 885606-83-7P
 885606-84-8P 885606-86-0P 885606-88-2P
 885606-90-6P 885606-94-0P 885606-95-1P
 885606-96-2P 885606-97-3P 885606-99-5P
 885607-00-1P 885607-01-2P 885607-02-3P
 885607-03-4P 885607-04-5P 885607-05-6P

885607-06-7P 885607-08-9P 885607-10-3P
 885607-12-5P 885607-14-7P 885607-15-8P
 885607-16-9P 885607-17-0P 885607-18-1P
 885607-20-5P 885607-21-6P 885607-22-7P
 885607-23-8P 885607-24-9P 885607-26-1P
 885607-27-2P 885607-28-3P 885607-29-4P
 885607-31-8P 885607-32-9P 885607-33-0P
 885607-34-1P 885607-35-2P 885607-36-3P
 885607-37-4P 885607-38-5P 885607-39-6P
 885607-40-9P 885607-46-5P 885607-47-6P
 885607-48-7P 885607-50-1P 885607-51-2P
 885607-59-0P 885607-61-4P 885607-62-5P
 885607-63-6P 885607-64-7P 885607-72-7P
 885607-73-8P 885607-74-9P 885607-75-0P
 885607-78-3P 885607-79-4P 885607-80-7P
 885607-81-8P 885607-82-9P 885607-83-0P
 885607-84-1P 885607-85-2P 885607-86-3P
 885607-87-4P 885607-88-5P 885607-89-6P
 885607-90-9P 885607-91-0P 885607-92-1P
 885607-93-2P 885607-94-3P 885607-95-4P
 885607-96-5P 885607-97-6P 885607-98-7P
 885607-99-8P 885608-00-4P 885608-01-5P
 885608-02-6P 885608-03-7P 885608-04-8P
 956407-57-1P 956407-58-2P 956407-59-3P
 956407-60-6P 956407-62-8P 956407-63-9P
 956407-64-0P 956407-65-1P 956407-67-3P
 956407-68-4P 956407-69-5P 956407-70-8P
 956407-71-9P 956407-72-0P 956407-73-1P
 956407-74-2P 956407-76-4P 956407-77-5P
 956407-78-6P 956407-79-7P 956407-80-0P
 956407-81-1P 956407-82-2P 956407-83-3P
 956407-84-4P 956407-85-5P 956407-86-6P
 956407-87-7P 956407-89-9P 956407-90-2P
 956407-91-3P 956407-95-7P 956407-96-8P
 956407-97-9P 956407-98-0P 956407-99-1P
 956408-00-7P 956408-02-9P 956408-03-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of indazole compds. as CGRP-receptor antagonists)

RN 885606-79-1 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[(7R)-
 3,6,7,8,9,10-hexahydro-8-oxo-9-(phenylmethyl)pyrazolo[3,4-i][2]benzazepin-
 7-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 885606-81-5 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[(7R)-3,6,7,8,9,10-hexahydro-9-methyl-8-oxopyrazolo[3,4-i][2]benzazepin-7-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 885606-83-7 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[(7R)-3,6,7,8,9,10-hexahydro-8-oxo-9-[2-(1-piperidinyl)ethyl]pyrazolo[3,4-i][2]benzazepin-7-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 885606-84-8 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[(7R)-3,6,7,8,9,10-hexahydro-8-oxo-9-[2-(1-pyrrolidinyl)ethyl]pyrazolo[3,4-i][2]benzazepin-7-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 885606-86-0 CAPLUS


CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[(7R)-9-[2-(dimethylamino)ethyl]-3,6,7,8,9,10-hexahydro-8-oxopyrazolo[3,4-i][2]benzazepin-7-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 885606-88-2 CAPLUS


CN 6H-Pyrazolo[3,4-g]quinolin-6-one, 7-[2-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-oxoethyl]-5-(2,2-dimethylpropyl)-1,5,7,8-tetrahydro- (CA INDEX NAME)



RN 885606-90-6 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[(7R)-3,6,7,8,9,10-hexahydro-9-[2-(4-morpholinyl)ethyl]-8-oxopyrazolo[3,4-i][2]benzazepin-7-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 885606-94-0 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[(7R)-3,6,7,8,9,10-hexahydro-8-oxo-9-[(1S)-1-phenylethyl]pyrazolo[3,4-i][2]benzazepin-7-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 885606-95-1 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[(7R)-3,6,7,8,9,10-hexahydro-8-oxo-9-[(1R)-1-phenylethyl]pyrazolo[3,4-i][2]benzazepin-7-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 885606-96-2 CAPLUS

CN 1-Piperidinecarboxamide, N-[(7R)-4-chloro-3,6,7,8,9,10-hexahydro-8-oxo-9-(phenylmethyl)pyrazolo[3,4-i][2]benzazepin-7-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885606-97-3 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[(7R)-3,6,7,8,9,10-hexahydro-8-oxo-9-[[4-(trifluoromethyl)phenyl]methyl]pyrazolo[3,4-i][2]benzazepin-7-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 885606-99-5 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[(7R)-3,6,7,8,9,10-hexahydro-9-(1-methylethyl)-8-oxopyrazolo[3,4-i][2]benzazepin-7-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-00-1 CAPLUS

CN 1-Piperidinecarboxamide, 4-[(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[(7R)-9-(3,3-dimethylbutyl)-3,6,7,8,9,10-hexahydro-8-oxopyrazolo[3,4-i][2]benzazepin-7-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-01-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(7R)-7-[[[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]carbonyl]amino]-6,7,8,10-tetrahydro-8-oxopyrazolo[3,4-i][2]benzazepin-9(3H)-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-02-3 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[(7R)-3,6,7,8,9,10-hexahydro-8-oxo-9-(4-piperidinyl)pyrazolo[3,4-i][2]benzazepin-7-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-03-4 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 7-[2-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-oxoethyl]-9-(2,2-dimethylpropyl)-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-04-5 CAPLUS

CN 1-Piperidinecarboxamide, N-[(7R)-4-chloro-9-(2,2-dimethylpropyl)-3,6,7,8,9,10-hexahydro-8-oxopyrazolo[3,4-i][2]benzazepin-7-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-05-6 CAPLUS


CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-oxoethyl]-9-(2,2-dimethylpropyl)-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 885607-06-7 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[9-(2,2-dimethylpropyl)-3,6,7,8,9,10-hexahydro-8-oxopyrazolo[3,4-i][2]benzazepin-7-yl]- (CA INDEX NAME)




RN 885607-08-9 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[3,6,7,8,9,10-hexahydro-9-(2-methylpropyl)-8-oxopyrazolo[3,4-i][2]benzazepin-7-yl]- (CA INDEX NAME)






RN 885607-10-3 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[3,6,7,8,9,10-hexahydro-8-oxo-9-[2-(4-pyridinyl)ethyl]pyrazolo[3,4-i][2]benzazepin-7-yl]- (CA INDEX NAME)




RN 885607-12-5 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[3,6,7,8,9,10-hexahydro-8-oxo-9-(4-pyridinylmethyl)pyrazolo[3,4-i][2]benzazepin-7-yl]- (CA INDEX NAME)




RN 885607-16-9 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-(2,3,4,5-tetrahydro-8-hydroxy-2-methyl-3-oxo-1H-2-benzazepin-4-yl)- (CA INDEX NAME)




RN 885607-17-0 CAPLUS

CN 1-Piperidinecarboxamide, N-(7,9-dichloro-2,3,4,5-tetrahydro-8-hydroxy-2-methyl-3-oxo-1H-2-benzazepin-4-yl)-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (CA INDEX NAME)



RN 885607-18-1 CAPLUS


CN 1-Piperidinecarboxamide, N-(7,9-dibromo-2,3,4,5-tetrahydro-8-hydroxy-2-methyl-3-oxo-1H-2-benzazepin-4-yl)-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (CA INDEX NAME)



RN 885607-20-5 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 7-[2-[4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)-1-piperidinyl]-2-oxoethyl]-9-(2,2-dimethylpropyl)-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-21-6 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[(6R)-1,5,6,7,8,9-hexahydro-7-oxo-8-(phenylmethyl)pyrazolo[4,3-h][2]benzazepin-6-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-22-7 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 7-[2-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(phenylmethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-23-8 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 9-(2,2-dimethylpropyl)-7-[2-[4-(8-fluoro-1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-24-9 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-9-(2,2-dimethylpropyl)-7-[2-[4-(8-fluoro-1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-26-1 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 7-[2-[4-(1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-9-(2,2-dimethylpropyl)-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-27-2 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-9-(2,2-dimethylpropyl)-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-28-3 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)-1-piperidinyl]-2-oxoethyl]-9-(2,2-dimethylpropyl)-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-29-4 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-[2,3-dihydro-2-oxo-4-(2-pyridinyl)-1H-imidazol-1-yl]-1-piperidinyl]-2-oxoethyl]-9-(2,2-dimethylpropyl)-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-31-8 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-9-(2,2-dimethylpropyl)-7-[2-[4-(8-fluoro-1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-32-9 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(3,4-dihydro-3-oxo-2-quinoxaliny)-1-piperidinyl]-2-oxoethyl]-9-(2,2-dimethylpropyl)-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-33-0 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(4-pyridinylmethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-34-1 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(8-fluoro-1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(4-pyridinylmethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-35-2 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(8-fluoro-1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(4-pyridinylmethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-36-3 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(4-pyridinylmethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-37-4 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(4-pyridinylmethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-38-5 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(1H-imidazol-2-ylmethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-39-6 CAPLUS

CN 1-Piperidinecarboxamide, N-[(4R)-8-amino-2,3,4,5-tetrahydro-7-methyl-3-oxo-2-(phenylmethyl)-1H-2-benzazepin-4-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-40-9 CAPLUS


CN 1-Piperidinecarboxamide, N-[(4R)-8-amino-2,3,4,5-tetrahydro-9-methyl-3-oxo-2-(phenylmethyl)-1H-2-benzazepin-4-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 885607-46-5 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(7R)-9-(1-acetyl-4-piperidinyl)-3,6,7,8,9,10-hexahydro-8-oxopyrazolo[3,4-i][2]benzazepin-7-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 885607-47-6 CAPLUS
 CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[(7R)-3,6,7,8,9,10-hexahydro-8-oxo-9-(3-pyrrolidinyl)pyrazolo[3,4-i][2]benzazepin-7-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 885607-48-7 CAPLUS
 CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 7-[2-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]ethyl]-9-(2,2-dimethylpropyl)-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-50-1 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 7-[2-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-oxoethyl]-9-(2,2-dimethylpropyl)-6,7,9,10-tetrahydro-, (7R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-51-2 CAPLUS

CN 1-Piperidinecarboxamide, N-[(7R)-9-(2,2-dimethylpropyl)-3,6,7,8,9,10-hexahydro-8-oxopyrazolo[3,4-i][2]benzazepin-7-yl]-4-(1,2,3,4-tetrahydro-2-oxo-3-quinolinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-59-0 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-61-4 CAPLUS

CN 2,4-Imidazolidinedione, 3-[1-[2-[(7S)-4-chloro-9-(2,2-dimethylpropyl)-3,6,7,8,9,10-hexahydro-8-oxopyrazolo[3,4-i][2]benzazepin-7-yl]acetyl]-4-piperidinyl]-1-phenyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-62-5 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(1,4-dihydro-2-oxopyrido[2,3-d]pyrimidin-3(2H)-yl)-1-piperidinyl]-2-oxoethyl]-9-(2,2-dimethylpropyl)-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-63-6 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(1,2-dihydro-2-oxo-1,8-naphthyridin-3-yl)-1-piperidinyl]-2-oxoethyl]-9-(2,2-dimethylpropyl)-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-64-7 CAPLUS


CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(1,2-dihydro-2-oxo-1,6-naphthyridin-3-yl)-1-piperidinyl]-2-oxoethyl]-9-(2,2-dimethylpropyl)-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 885607-72-7 CAPLUS


CN 1-Piperidinecarboximidamide, N-cyano-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N'-[9-(2,2-dimethylpropyl)-3,6,7,8,9,10-hexahydro-8-oxopyrazolo[3,4-i][2]benzazepin-7-yl]- (CA INDEX NAME)



RN 885607-73-8 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(1,2-dihydro-2-oxo-1,8-naphthyridin-3-yl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-74-9 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-75-0 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(8-fluoro-1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-78-3 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-bromo-7-[2-[4-(1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-9-(2,2-dimethylpropyl)-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-79-4 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-bromo-9-(2,2-dimethylpropyl)-7-[2-[4-(8-fluoro-1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-80-7 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-bromo-7-[2-[4-(1,2-dihydro-2-oxo-1,8-naphthyridin-3-yl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-81-8 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-bromo-7-[2-[4-(1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-82-9 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-bromo-7-[2-[4-(8-fluoro-1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-83-0 CAPLUS

CN 1-Piperidinecarboximidamide, N-[(7R)-4-chloro-9-(2,2-dimethylpropyl)-3,6,7,8,9,10-hexahydro-8-oxopyrazolo[3,4-i][2]benzazepin-7-yl]-N'-cyano-4-(1,2-dihydro-2-oxo-3-quinolinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-84-1 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 7-[2-[4-(1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-9-(2,2-dimethylpropyl)-6,7,9,10-tetrahydro-4-methyl-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-85-2 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 9-(2,2-dimethylpropyl)-7-[2-[4-(8-fluoro-1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-4-methyl-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-86-3 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 7-[2-[4-(1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-4-methyl-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-87-4 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 7-[2-[4-(8-fluoro-1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-4-methyl-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-88-5 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 7-[2-[4-(1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-9-(2,2-dimethylpropyl)-6,7,9,10-tetrahydro-4-(1-methylethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-89-6 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 9-(2,2-dimethylpropyl)-7-[2-[4-(8-fluoro-1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-4-(1-methylethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-90-9 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 7-[2-[4-(1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-4-(1-methylethyl)-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-91-0 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 7-[2-[4-(8-fluoro-1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-4-(1-methylethyl)-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-92-1 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 7-[2-[4-(1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-4-(1-methylethenyl)-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-93-2 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 7-[2-[4-(8-fluoro-1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-4-(1-methylethenyl)-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-94-3 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-ethyl-7-[2-[4-(8-fluoro-1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-95-4 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-bromo-9-(cyclopropylmethyl)-7-[2-[4-(1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-96-5 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-bromo-9-(cyclopropylmethyl)-7-[2-[4-(8-fluoro-1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-97-6 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-bromo-7-[2-[4-(1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(2-methoxyethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-98-7 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-bromo-7-[2-[4-(8-fluoro-1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(2-methoxyethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-99-8 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(6,7-difluoro-1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-9-(2,2-dimethylpropyl)-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885608-00-4 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(7-chloro-1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-9-(2,2-dimethylpropyl)-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885608-01-5 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(8-chloro-1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-9-(2,2-dimethylpropyl)-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885608-02-6 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-9-(2,2-dimethylpropyl)-7-[2-[4-(5-fluoro-1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885608-03-7 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-9-(2,2-dimethylpropyl)-7-[2-[4-(7-fluoro-1,2-dihydro-2-oxo-1,8-naphthyridin-3-yl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885608-04-8 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-9-(2,2-dimethylpropyl)-7-[2-[4-(7-fluoro-1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 956407-57-1 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-6,7,9,10-tetrahydro-7-[2-oxo-2-[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]ethyl]-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 956407-58-2 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(2,3-dihydro-2-oxo-3-phenyl-1H-imidazol-1-yl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 956407-59-3 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(2,3-dihydro-2-oxo-1H-imidazol-1-yl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 956407-60-6 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 956407-62-8 CAPLUS

CN 1H-Imidazole-4-carbonitrile, 1-[1-[2-[(7S)-4-chloro-3,6,7,8,9,10-hexahydro-8-oxo-9-(2,2,2-trifluoroethyl)pyrazolo[3,4-i][2]benzazepin-7-yl]acetyl]-4-piperidinyl]-2,3-dihydro-2-oxo- (CA INDEX NAME)


Absolute stereochemistry.



RN 956407-63-9 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-[3-(2-fluorophenyl)-2,3-dihydro-2-oxo-1H-imidazol-1-yl]-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 956407-64-0 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-[3-(2-fluorophenyl)-2-oxo-1-imidazolidinyl]-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 956407-65-1 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 956407-67-3 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(2,3-dihydro-4-oxido-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 956407-68-4 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 1,4-dibromo-7-[2-[4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 956407-69-5 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 1,4-dibromo-6,7,9,10-tetrahydro-7-[2-oxo-2-[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]ethyl]-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 956407-70-8 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(9-fluoro-1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 956407-71-9 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-6,7,9,10-tetrahydro-7-[2-oxo-2-[4-(1,2,4,5-tetrahydro-2-oxo-3H-pyrido[2,3-d]-1,3-diazepin-3-yl)-1-piperidinyl]ethyl]-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 956407-72-0 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-6,7,9,10-tetrahydro-7-[2-oxo-2-[4-(1,2,4,5-tetrahydro-2-oxo-3H-pyrido[3,2-d]-1,3-diazepin-3-yl)-1-piperidinyl]ethyl]-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 956407-73-1 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(4-fluoro-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 956407-74-2 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-bromo-1-chloro-6,7,9,10-tetrahydro-7-[2-oxo-2-[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]ethyl]-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 956407-76-4 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-bromo-1-chloro-7-[2-[4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 956407-77-5 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 1,4-dichloro-6,7,9,10-tetrahydro-7-[2-oxo-2-[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]ethyl]-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 956407-78-6 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 1,4-dichloro-7-[2-[4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 956407-79-7 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 1,4-dichloro-6,7,9,10-tetrahydro-7-[2-oxo-2-[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyloxy]ethyl]-9-[2-(1-piperidinyloxy)ethyl]-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 956407-80-0 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 1,4-dichloro-7-[2-[4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-1-piperidinyloxy]-2-oxoethyl]-6,7,9,10-tetrahydro-9-[2-(1-piperidinyloxy)ethyl]-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 956407-81-1 CAPLUS

CN Pyrrolo[2,3-i]-2-benzazepin-3(2H)-one, 7-chloro-4-[2-[4-(4,5-dihydro-1-methyl-5-oxo-1H-pyrrolo[3,2-b]pyridin-6-yl)-1-piperidinyl]-2-oxoethyl]-2-(2,2-dimethylpropyl)-1,4,5,8-tetrahydro-, (4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 956407-82-2 CAPLUS

CN Pyrrolo[2,3-i]-2-benzazepin-3(2H)-one, 7-chloro-4-[2-[4-(4,5-dihydro-5-oxothieno[3,2-b]pyridin-6-yl)-1-piperidinyl]-2-oxoethyl]-2-(2,2-dimethylpropyl)-1,4,5,8-tetrahydro-, (4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 956407-83-3 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 7-[2-[4-(3-bromo-4,5-dihydro-5-oxothieno[3,2-b]pyridin-6-yl)-1-piperidinyl]-2-oxoethyl]-4-chloro-9-(2,2-dimethylpropyl)-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 956407-84-4 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 7-[2-[4-(2-bromo-4,5-dihydro-5-oxothieno[3,2-b]pyridin-6-yl)-1-piperidinyl]-2-oxoethyl]-4-chloro-9-(2,2-dimethylpropyl)-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 956407-85-5 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(2-chloro-4,5-dihydro-5-oxothieno[3,2-b]pyridin-6-yl)-1-piperidinyl]-2-oxoethyl]-9-(2,2-dimethylpropyl)-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 956407-86-6 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(3-chloro-4,5-dihydro-5-oxothieno[3,2-b]pyridin-6-yl)-1-piperidinyl]-2-oxoethyl]-9-(2,2-dimethylpropyl)-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 956407-87-7 CAPLUS

CN Pyrrolo[2,3-i]-2-benzazepin-3(2H)-one, 7-chloro-4-[2-[4-(4,5-dihydro-5-oxo-1H-pyrrolo[3,2-b]pyridin-6-yl)-1-piperidinyl]-2-oxoethyl]-2-(2,2-dimethylpropyl)-1,4,5,8-tetrahydro-, (4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 956407-89-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (7R)-4-chloro-3,6,7,8,9,10-hexahydro-8-oxo-9-(2,2,2-trifluoroethyl)pyrazolo[3,4-i][2]benzazepin-7-yl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 956407-90-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-, (7R)-4-chloro-3,6,7,8,9,10-hexahydro-8-oxo-9-(2,2,2-trifluoroethyl)pyrazolo[3,4-i][2]benzazepin-7-yl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 956407-91-3 CAPLUS

CN 2,4-Imidazolidinedione, 5-[1-[2-[(7S)-4-chloro-3,6,7,8,9,10-hexahydro-8-oxo-9-(2,2,2-trifluoroethyl)pyrazolo[3,4-i][2]benzazepin-7-yl]acetyl]-4-piperidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 956407-95-7 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 956407-96-8 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-1-piperidinyl]-2-oxoethyl]-3-ethyl-6,7,9,10-tetrahydro-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 956407-97-9 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-3-(phenylmethyl)-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 956407-98-0 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-6,7,9,10-tetrahydro-3-methyl-7-[2-oxo-2-[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]ethyl]-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 956407-99-1 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-6,7,9,10-tetrahydro-7-[2-oxo-2-[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]ethyl]-3-propyl-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 956408-00-7 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-6,7,9,10-tetrahydro-3-(methoxymethyl)-7-[2-oxo-2-[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]ethyl]-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 956408-02-9 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-6,7,9,10-tetrahydro-3-(2-methoxyethyl)-7-[2-oxo-2-[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]ethyl]-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 956408-03-0 CAPLUS


CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 6,7,9,10-tetrahydro-7-[2-oxo-2-[4-(1,2,3,4-tetrahydro-2-oxo-3-quinolinyl)-1-piperidinyl]ethyl]-9-(phenylmethyl)-, (7S)- (CA INDEX NAME)

Absolute stereochemistry.



IT 885608-96-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of indazole compds. as CGRP-receptor antagonists)
 RN 885608-96-8 CAPLUS
 CN Carbamic acid, N-[(4R)-4-[[[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-
 piperidinyl]carbonyl]amino]-2,3,4,5-tetrahydro-7-methyl-3-oxo-2-
 (phenylmethyl)-1H-2-benzazepin-8-yl]-, 1,1-dimethylethyl ester (CA INDEX
 NAME)

Absolute stereochemistry.



L5 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2007:1274981 CAPLUS Full-text
 DN 147:522238
 TI Preparation of indazole compounds as CGRP-receptor antagonists
 IN Mercer, Stephen E.; Chaturvedula, Prasad V.
 PA Bristol-Myers Squibb Company, USA
 SO U.S. Pat. Appl. Publ., 116pp.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2007259850	A1	20071108	US 2007-742615	20070501
	WO 2007130927	A2	20071115	WO 2007-US67857	20070501
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRAI	US 2006-796702P	P	20060502		
OS	MARPAT 147:522238				
GI					

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Bicyclic and tricyclic indazole compds. I, wherein A is O or NR1 provided that when A is NR1 then R1 is not H; R1 is C1-6-alkyl, C2-6-alkenyl, C3-7-cycloalkyl, C5-7-cyclo-alkenyl, C1-6-(C3-7-cycloalkyl)alkyl, C1-6-haloalkyl, C1-6-(C1-6-alkoxy)alkyl, C1-6-(Ar)alkyl, C1-6-(NR7R8)alkyl, N-(R9)-pyrrolidinyl or N-(R9)-piperidinyl; R2 is H, halo, or C1-6-alkyl; R3 is H, C1-6-alkyl, or C2-6-alkenyl; R4 is H, halo or C1-6-alkyl, or C2-6-alkenyl; R5 is H or C1-6-alkyl; R6 is H, C1-6-alkyl, heterocyclyl; R7 is hydrogen or C1-6-alkyl; R8 is hydrogen or C1-6-alkyl; or NR7R8 taken together is selected from the group consisting of pyrrolidinyl, piperidinyl, N-(R9)-piperazinyl, morpholinyl, and thio-morpholinyl; R9 is hydrogen, C1-6-alkyl, C1-6-alkylcarbonyl, or C1-6-alkoxycarbonyl; were prepared as CGRP-receptor antagonists, and may be used in therapy for treatment of migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors. Thus, title II was prepared and tested in vitro as human CGRP-receptor antagonist (IC50 = 0.1-10 nM).

IT 885606-79-1P 885606-81-5P 885606-83-7P
 885606-84-8P 885606-86-0P 885606-88-2P
 885606-90-6P 885606-94-0P 885606-95-1P
 885606-96-2P 885606-97-3P 885606-99-5P
 885607-00-1P 885607-01-2P 885607-02-3P
 885607-03-4P 885607-04-5P 885607-05-6P
 885607-06-7P 885607-08-9P 885607-10-3P
 885607-12-5P 885607-14-7P 885607-15-8P
 885607-16-9P 885607-17-0P 885607-18-1P

885607-20-5P 885607-21-6P 885607-22-7P
 885607-23-8P 885607-24-9P 885607-26-1P
 885607-27-2P 885607-28-3P 885607-29-4P
 885607-31-8P 885607-32-9P 885607-33-0P
 885607-34-1P 885607-35-2P 885607-36-3P
 885607-37-4P 885607-38-5P 885607-39-6P
 885607-40-9P 885607-46-5P 885607-47-6P
 885607-48-7P 885607-50-1P 885607-51-2P
 885607-59-0P 885607-61-4P 885607-62-5P
 885607-63-6P 885607-64-7P 885607-72-7P
 885607-73-8P 885607-74-9P 885607-75-0P
 885607-78-3P 885607-79-4P 885607-80-7P
 885607-81-8P 885607-82-9P 885607-83-0P
 885607-84-1P 885607-85-2P 885607-86-3P
 885607-87-4P 885607-88-5P 885607-89-6P
 885607-90-9P 885607-91-0P 885607-92-1P
 885607-93-2P 885607-94-3P 885607-95-4P
 885607-96-5P 885607-97-6P 885607-98-7P
 885607-99-8P 885608-00-4P 885608-01-5P
 885608-02-6P 885608-03-7P 885608-04-8P
 956408-03-0P 956470-52-3P 956470-53-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of indazole compds. as CGRP-receptor antagonists)

RN 885606-79-1 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[(7R)-
 3,6,7,8,9,10-hexahydro-8-oxo-9-(phenylmethyl)pyrazolo[3,4-i][2]benzazepin-
 7-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 885606-81-5 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[(7R)-
 3,6,7,8,9,10-hexahydro-9-methyl-8-oxopyrazolo[3,4-i][2]benzazepin-7-yl]-
 (CA INDEX NAME)


Absolute stereochemistry.



RN 885606-83-7 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[(7R)-3,6,7,8,9,10-hexahydro-8-oxo-9-[2-(1-piperidinyl)ethyl]pyrazolo[3,4-i][2]benzazepin-7-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 885606-84-8 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[(7R)-3,6,7,8,9,10-hexahydro-8-oxo-9-[2-(1-pyrrolidinyl)ethyl]pyrazolo[3,4-i][2]benzazepin-7-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 885606-86-0 CAPLUS


CN 1-Piperidinecarboxamide, 4-((1R)-4-(2-(dimethylamino)ethyl)-1,4-dihydro-2-oxo-3H-quinazolin-1-yl)-N-((7R)-9-[2-(dimethylamino)ethyl]-3,6,7,8,9,10-hexahydro-8-oxopyrazolo[3,4-i][2]benzazepin-7-yl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 885606-88-2 CAPLUS


CN 6H-Pyrazolo[3,4-g]quinolin-6-one, 7-([2-[[4-(1,4-dihydro-2-oxo-3H-quinazolin-1-yl)-1-piperidinyl]-2-oxoethyl]-5-(2,2-dimethylpropyl)-1,5,7,8-tetrahydro-2H-benzazepin-7-yl]-2-(dimethylamino)ethyl)- (CA INDEX NAME)



RN 885606-90-6 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[(7R)-3,6,7,8,9,10-hexahydro-9-[2-(4-morpholinyl)ethyl]-8-oxopyrazolo[3,4-i][2]benzazepin-7-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 885606-94-0 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[(7R)-3,6,7,8,9,10-hexahydro-8-oxo-9-[(1S)-1-phenylethyl]pyrazolo[3,4-i][2]benzazepin-7-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 885606-95-1 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[(7R)-3,6,7,8,9,10-hexahydro-8-oxo-9-[(1R)-1-phenylethyl]pyrazolo[3,4-i][2]benzazepin-7-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 885606-96-2 CAPLUS

CN 1-Piperidinecarboxamide, N-[(7R)-4-chloro-3,6,7,8,9,10-hexahydro-8-oxo-9-(phenylmethyl)pyrazolo[3,4-i][2]benzazepin-7-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885606-97-3 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[(7R)-3,6,7,8,9,10-hexahydro-8-oxo-9-[[4-(trifluoromethyl)phenyl]methyl]pyrazolo[3,4-i][2]benzazepin-7-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 885606-99-5 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[(7R)-3,6,7,8,9,10-hexahydro-9-(1-methylethyl)-8-oxopyrazolo[3,4-i][2]benzazepin-7-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-00-1 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[(7R)-9-(3,3-dimethylbutyl)-3,6,7,8,9,10-hexahydro-8-oxopyrazolo[3,4-i][2]benzazepin-7-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-01-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(7R)-7-[[[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]carbonyl]amino]-6,7,8,10-tetrahydro-8-oxopyrazolo[3,4-i][2]benzazepin-9(3H)-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-02-3 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[(7R)-3,6,7,8,9,10-hexahydro-8-oxo-9-(4-piperidinyl)pyrazolo[3,4-i][2]benzazepin-7-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-03-4 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 7-[2-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-oxoethyl]-9-(2,2-dimethylpropyl)-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-04-5 CAPLUS

CN 1-Piperidinecarboxamide, N-[(7R)-4-chloro-9-(2,2-dimethylpropyl)-3,6,7,8,9,10-hexahydro-8-oxopyrazolo[3,4-i][2]benzazepin-7-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-05-6 CAPLUS


CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-oxoethyl]-9-(2,2-dimethylpropyl)-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 885607-06-7 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[9-(2,2-dimethylpropyl)-3,6,7,8,9,10-hexahydro-8-oxopyrazolo[3,4-i][2]benzazepin-7-yl]- (CA INDEX NAME)




RN 885607-08-9 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[3,6,7,8,9,10-hexahydro-9-(2-methylpropyl)-8-oxopyrazolo[3,4-i][2]benzazepin-7-yl]- (CA INDEX NAME)




RN 885607-10-3 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[3,6,7,8,9,10-hexahydro-8-oxo-9-[2-(4-pyridinyl)ethyl]pyrazolo[3,4-i][2]benzazepin-7-yl]- (CA INDEX NAME)




RN 885607-12-5 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[3,6,7,8,9,10-hexahydro-8-oxo-9-(4-pyridinylmethyl)pyrazolo[3,4-i][2]benzazepin-7-yl]- (CA INDEX NAME)




RN 885607-14-7 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-(3,6,7,8,9,10-hexahydro-4,9-dimethyl-8-oxopyrazolo[3,4-i][2]benzazepin-7-yl)- (CA INDEX NAME)




RN 885607-15-8 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[2,3,4,5-tetrahydro-2-methyl-3-oxo-8-(phenylmethoxy)-1H-2-benzazepin-4-yl]- (CA INDEX NAME)




RN 885607-16-9 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-(2,3,4,5-tetrahydro-8-hydroxy-2-methyl-3-oxo-1H-2-benzazepin-4-yl)- (CA INDEX NAME)




RN 885607-17-0 CAPLUS

CN 1-Piperidinecarboxamide, N-(7,9-dichloro-2,3,4,5-tetrahydro-8-hydroxy-2-methyl-3-oxo-1H-2-benzazepin-4-yl)-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (CA INDEX NAME)



RN 885607-18-1 CAPLUS


CN 1-Piperidinecarboxamide, N-(7,9-dibromo-2,3,4,5-tetrahydro-8-hydroxy-2-methyl-3-oxo-1H-2-benzazepin-4-yl)-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (CA INDEX NAME)



RN 885607-20-5 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 7-[2-[4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)-1-piperidinyl]-2-oxoethyl]-9-(2,2-dimethylpropyl)-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-21-6 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[(6R)-1,5,6,7,8,9-hexahydro-7-oxo-8-(phenylmethyl)pyrazolo[4,3-h][2]benzazepin-6-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-22-7 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 7-[2-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(phenylmethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-23-8 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 9-(2,2-dimethylpropyl)-7-[2-[4-(8-fluoro-1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-24-9 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-9-(2,2-dimethylpropyl)-7-[2-[4-(8-fluoro-1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-26-1 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 7-[2-[4-(1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-9-(2,2-dimethylpropyl)-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-27-2 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-9-(2,2-dimethylpropyl)-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-28-3 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)-1-piperidinyl]-2-oxoethyl]-9-(2,2-dimethylpropyl)-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-29-4 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-[2,3-dihydro-2-oxo-4-(2-pyridinyl)-1H-imidazol-1-yl]-1-piperidinyl]-2-oxoethyl]-9-(2,2-dimethylpropyl)-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-31-8 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-9-(2,2-dimethylpropyl)-7-[2-[4-(8-fluoro-1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-32-9 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(3,4-dihydro-3-oxo-2-quinoxaliny)]-1-piperidinyl]-2-oxoethyl]-9-(2,2-dimethylpropyl)-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-33-0 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)]-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(4-pyridinylmethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-34-1 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(8-fluoro-1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(4-pyridinylmethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-35-2 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(8-fluoro-1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(4-pyridinylmethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-36-3 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(4-pyridinylmethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-37-4 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(4-pyridinylmethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-38-5 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(1H-imidazol-2-ylmethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-39-6 CAPLUS

CN 1-Piperidinecarboxamide, N-[(4R)-8-amino-2,3,4,5-tetrahydro-7-methyl-3-oxo-2-(phenylmethyl)-1H-2-benzazepin-4-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-40-9 CAPLUS

CN 1-Piperidinecarboxamide, N-[(4R)-8-amino-2,3,4,5-tetrahydro-9-methyl-3-oxo-2-(phenylmethyl)-1H-2-benzazepin-4-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-46-5 CAPLUS

CN 1-Piperidinecarboxamide, N-[(7R)-9-(1-acetyl-4-piperidiny1)-3,6,7,8,9,10-hexahydro-8-oxopyrazolo[3,4-i][2]benzazepin-7-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-47-6 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[(7R)-3,6,7,8,9,10-hexahydro-8-oxo-9-(3-pyrrolidinyl)pyrazolo[3,4-i][2]benzazepin-7-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-48-7 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 7-[2-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]ethyl]-9-(2,2-dimethylpropyl)-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-50-1 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 7-[2-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-oxoethyl]-9-(2,2-dimethylpropyl)-6,7,9,10-tetrahydro-, (7R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-51-2 CAPLUS

CN 1-Piperidinecarboxamide, N-[(7R)-9-(2,2-dimethylpropyl)-3,6,7,8,9,10-hexahydro-8-oxopyrazolo[3,4-i][2]benzazepin-7-yl]-4-(1,2,3,4-tetrahydro-2-oxo-3-quinolinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-59-0 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-61-4 CAPLUS

CN 2,4-Imidazolidinedione, 3-[1-[2-[(7S)-4-chloro-9-(2,2-dimethylpropyl)-3,6,7,8,9,10-hexahydro-8-oxopyrazolo[3,4-i][2]benzazepin-7-yl]acetyl]-4-piperidinyl]-1-phenyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-62-5 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(1,4-dihydro-2-oxopyrido[2,3-d]pyrimidin-3(2H)-yl)-1-piperidinyl]-2-oxoethyl]-9-(2,2-dimethylpropyl)-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-63-6 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(1,2-dihydro-2-oxo-1,8-naphthyridin-3-yl)-1-piperidinyl]-2-oxoethyl]-9-(2,2-dimethylpropyl)-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-64-7 CAPLUS


CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(1,2-dihydro-2-oxo-1,6-naphthyridin-3-yl)-1-piperidinyl]-2-oxoethyl]-9-(2,2-dimethylpropyl)-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 885607-72-7 CAPLUS


CN 1-Piperidinecarboximidamide, N-cyano-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N'-[9-(2,2-dimethylpropyl)-3,6,7,8,9,10-hexahydro-8-oxopyrazolo[3,4-i][2]benzazepin-7-yl]- (CA INDEX NAME)



RN 885607-73-8 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(1,2-dihydro-2-oxo-1,8-naphthyridin-3-yl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-74-9 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-75-0 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(8-fluoro-1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-78-3 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-bromo-7-[2-[4-(1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-9-(2,2-dimethylpropyl)-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-79-4 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-bromo-9-(2,2-dimethylpropyl)-7-[2-[4-(8-fluoro-1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-80-7 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-bromo-7-[2-[4-(1,2-dihydro-2-oxo-1,8-naphthyridin-3-yl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-81-8 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-bromo-7-[2-[4-(1,2-dihydro-2-oxo-3-quinoliny)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-82-9 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-bromo-7-[2-[4-(8-fluoro-1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-83-0 CAPLUS

CN 1-Piperidinecarboximidamide, N-[(7R)-4-chloro-9-(2,2-dimethylpropyl)-3,6,7,8,9,10-hexahydro-8-oxopyrazolo[3,4-i][2]benzazepin-7-yl]-N'-cyano-4-(1,2-dihydro-2-oxo-3-quinolinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-84-1 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 7-[2-[4-(1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-9-(2,2-dimethylpropyl)-6,7,9,10-tetrahydro-4-methyl-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-85-2 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 9-(2,2-dimethylpropyl)-7-[2-[4-(8-fluoro-1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-4-methyl-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-86-3 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 7-[2-[4-(1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-4-methyl-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-87-4 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 7-[2-[4-(8-fluoro-1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-4-methyl-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-88-5 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 7-[2-[4-(1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-9-(2,2-dimethylpropyl)-6,7,9,10-tetrahydro-4-(1-methylethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-89-6 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 9-(2,2-dimethylpropyl)-7-[2-[4-(8-fluoro-1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-4-(1-methylethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-90-9 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 7-[2-[4-(1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-4-(1-methylethyl)-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-91-0 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 7-[2-[4-(8-fluoro-1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-4-(1-methylethyl)-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-92-1 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 7-[2-[4-(1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-4-(1-methylethenyl)-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-93-2 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 7-[2-[4-(8-fluoro-1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-4-(1-methylethenyl)-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-94-3 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-ethyl-7-[2-[4-(8-fluoro-1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-95-4 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-bromo-9-(cyclopropylmethyl)-7-[2-[4-(1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-96-5 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-bromo-9-(cyclopropylmethyl)-7-[2-[4-(8-fluoro-1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-97-6 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-bromo-7-[2-[4-(1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(2-methoxyethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-98-7 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-bromo-7-[2-[4-(8-fluoro-1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(2-methoxyethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-99-8 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(6,7-difluoro-1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-9-(2,2-dimethylpropyl)-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885608-00-4 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(7-chloro-1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-9-(2,2-dimethylpropyl)-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885608-01-5 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(8-chloro-1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-9-(2,2-dimethylpropyl)-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885608-02-6 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-9-(2,2-dimethylpropyl)-7-[2-[4-(5-fluoro-1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885608-03-7 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-9-(2,2-dimethylpropyl)-7-[2-[4-(7-fluoro-1,2-dihydro-2-oxo-1,8-naphthyridin-3-yl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885608-04-8 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-9-(2,2-dimethylpropyl)-7-[2-[4-(7-fluoro-1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 956408-03-0 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 6,7,9,10-tetrahydro-7-[2-oxo-2-[4-(1,2,3,4-tetrahydro-2-oxo-3-quinolinyl)-1-piperidinyl]ethyl]-9-(phenylmethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 956470-52-3 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 1,4-dibromo-7-[2-[4-(1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 956470-53-4 CAPLUS


CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 1,4-dibromo-7-[2-[4-(8-fluoro-1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)

Absolute stereochemistry.




IT 885608-26-4P 885608-96-8P 885609-01-8P
 885609-11-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of indazole compds. as CGRP-receptor antagonists)
 RN 885608-26-4 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(7R)-3-acetyl-3,6,7,8,9,10-hexahydro-8-oxo-9-
 (phenylmethyl)pyrazolo[3,4-i][2]benzazepin-7-yl]-4-(1,4-dihydro-2-oxo-
 3(2H)-quinazolinyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 885608-96-8 CAPLUS
 CN Carbamic acid, N-[(4R)-4-[[[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-
 piperidinyl]carbonyl]amino]-2,3,4,5-tetrahydro-7-methyl-3-oxo-2-
 (phenylmethyl)-1H-2-benzazepin-8-yl]-, 1,1-dimethylethyl ester (CA INDEX
 NAME)


Absolute stereochemistry.



RN 885609-01-8 CAPLUS

CN Carbamic acid, N-[(4R)-4-[[[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]carbonyl]amino]-2,3,4,5-tetrahydro-9-methyl-3-oxo-2-(phenylmethyl)-1H-2-benzazepin-8-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 885609-11-0 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 3-[(7R)-7-[[[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]carbonyl]amino]-6,7,8,10-tetrahydro-8-oxopyrazolo[3,4-i][2]benzazepin-9(3H)-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2007:1207338 CAPLUS Full-text
 DN 147:469343
 TI Preparation of N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide salts as calcitonin gene-related peptide (CGRP) antagonists.
 IN Belyk, Kevin
 PA Merck & Co., Inc., USA
 SO PCT Int. Appl., 34pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007120592	A1	20071025	WO 2007-US8703	20070406
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW:				
	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRAI US 2006-790645P P 20060410

AB N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide (I) potassium salt and its hydrate and ethanolate were prepared I was prepared by coupling (3R,6S)-3-amino-6-(2,3-difluorophenyl)-1-(2,2,2-trifluoroethyl)azepan-2-one hydrochloride and 2-oxo-1-(4-piperidinyl)-2,3-dihydro-1H-imidazo[4,5-b]pyridine dihydrochloride with 1,1'-carbonyldiimidazole. I potassium salt ethanolate was prepared in 84% yield by treatment of I with KOtBu in EtOH.


IT 915312-27-5P 953077-35-5P 953077-36-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of difluorophenyloxotrifluoroethylazepanyloxodihydroimidazopyridinylpiperidinecarboxamide salts as calcitonin gene-related peptide antagonists)

RN 915312-27-5 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-2-oxo-1-(2,2,2-trifluoroethyl)-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-, potassium salt (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● K

RN 953077-35-5 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-2-oxo-1-(2,2,2-trifluoroethyl)-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-, compd. with ethanol, potassium salt (1:1:1)
 (CA INDEX NAME)

CM 1

CRN 781649-09-0
 CMF C26 H27 F5 N6 O3

Absolute stereochemistry.



CM 2

CRN 64-17-5
 CMF C2 H6 O


H₃C—CH₂—OH

RN 953077-36-6 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-2-oxo-

1-(2,2,2-trifluoroethyl)-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-, potassium salt, hydrate (1:1:1) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




● K

PAGE 2-A

● H₂O

IT 781649-09-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of
 difluorophenyloxotrifluoroethylazepanyloxodihydroimidazopyridinylpiperidinecarboxamide salts as calcitonin gene-related peptide antagonists)
 RN 781649-09-0 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-2-oxo-1-(2,2,2-trifluoroethyl)-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2007:1204835 CAPLUS Full-text

DN 147:486345

TI Process for preparation of (3R,6S)-3-amino-6-(2,3-difluorophenyl)-1-(2,2,2-trifluoroethyl)azepan-2-one hydrochloride

IN Palucki, Michael; Davies, Ian; Steinhuebel, Dietrich; Rosen, Jonathan

PA Merck & Co., Inc., USA

SO PCT Int. Appl., 42pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2007120589	A2	20071025	WO 2007-US8700	20070406
	WO 2007120589	A3	20071227		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				

PRAI US 2006-790646P P 20060410

OS CASREACT 147:486345

AB This invention pertains to an efficient and economical process for the preparation of (3R,6S)-3-amino-6-(2,3-difluorophenyl)-1-(2,2,2-trifluoroethyl)azepan-2-one hydrochloride as an intermediate for the synthesis of a CGRP antagonist. For example, (3S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)-2,3,4,7-tetrahydro-1H-azepin-3-ammonium di-p-toluoyl-L-tartrate (preparation given) was hydrogenated in presence of a cis-selective palladium catalyst to form (3S,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-ammonium di-p-toluoyl-L-tartrate. The intermediate formed above was treated with Et₃N and 2-hydroxy-5-nitrobenzaldehyde to form (3R,6S)-3-amino-6-(2,3-difluorophenyl)-1-(2,2,2-trifluoroethyl)azepan-2-one, which was further treated with HCl to give the title compound as a final product.

IT 781649-09-0P


RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of (3R,6S)-3-amino-6-(2,3-difluorophenyl)-1-(2,2,2-trifluoroethyl)azepan-2-one hydrochloride)

RN 781649-09-0 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-2-oxo-1-(2,2,2-trifluoroethyl)-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.



IT 953077-35-5P

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(preparation of (3R,6S)-3-amino-6-(2,3-difluorophenyl)-1-(2,2,2-trifluoroethyl)azepan-2-one hydrochloride)

RN 953077-35-5 CAPLUS


CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-2-oxo-1-(2,2,2-trifluoroethyl)-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-, compd. with ethanol, potassium salt (1:1:1) (CA INDEX NAME)

CM 1

CRN 781649-09-0

CMF C26 H27 F5 N6 O3

Absolute stereochemistry.



CM 2

CRN 64-17-5

CMF C2 H6 O

H₃C—CH₂—OH

L5 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2007:1204701 CAPLUS Full-text
 DN 147:469342
 TI Process for preparation of a CGRP antagonist
 IN Belyk, Kevin; Rivera, Nelo
 PA Merck & Co., Inc., USA
 SO PCT Int. Appl., 44pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007120591	A1	20071025	WO 2007-US8702	20070406
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW:				
	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRAI US 2006-790704P P 20060410

OS CASREACT 147:469342

AB This invention pertains to an efficient and economical process for the preparation of N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide and the potassium salt ethanolate thereof, which can be used as a CGRP antagonist. For example, (3R,6S)-3-amino-6-(2,3-difluorophenyl)-1-(2,2,2-trifluoroethyl)azepan-2-one (preparation give) and 1-piperidin-4-yl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one dihydrochloride (preparation given) was coupled with 1,1'-carbonyldiimidazole, as carbonyl source, in THF in presence of triethylamine under heating at 60° overnight to give the title compound. The product obtained above was treated with potassium tert-butoxide in ethanol at 45 °C overnight to give the potassium salt ethanolate thereof.


IT 781649-09-0P

RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of CGRP antagonist)

RN 781649-09-0 CAPLUS


CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-2-oxo-1-(2,2,2-trifluoroethyl)-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.



IT 953077-35-5P 953081-44-2P
 RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP
 (Preparation)
 (preparation of CGRP antagonist)
 RN 953077-35-5 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-2-oxo-
 1-(2,2,2-trifluoroethyl)-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-
 imidazo[4,5-b]pyridin-1-yl)-, compd. with ethanol, potassium salt (1:1:1)
 (CA INDEX NAME)
 CM 1
 CRN 781649-09-0
 CMF C26 H27 F5 N6 O3

Absolute stereochemistry.



CM 2
 CRN 64-17-5
 CMF C2 H6 O

H₃C—CH₂—OH

RN 953081-44-2 CAPLUS


CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-2-oxo-1-(2,2,2-trifluoroethyl)-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-, compd. with ethanol, potassium salt, hydrate (1:1:1:1) (CA INDEX NAME)

CM 1

CRN 781649-09-0

CMF C26 H27 F5 N6 O3

Absolute stereochemistry.



CM 2

CRN 64-17-5

CMF C2 H6 O

H₃C—CH₂—OH

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 7 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2007:1204423 CAPLUS Full-text

DN 147:486440

TI Process for preparation of 1-piperidin-4-yl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one dihydrochloride

IN McLaughlin, Mark; Palucki, Michael; Marcantonio, Karen

PA Merck & Co., Inc., USA

SO PCT Int. Appl., 48pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2007120590	A2	20071025	WO 2007-US8701	20070406
	WO 2007120590	A3	20071213		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				

PRAI US 2006-790702P P 20060410

OS CASREACT 147:486440

AB This invention pertains to an efficient and economical process for the preparation of 1-piperidin-4-yl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one dihydrochloride as an intermediate for the synthesis of a CGRP antagonist. For example, 3-amino-2-chloropyridine was reacted with Et 4-oxo-1-piperidinecarboxylate to form 4-[(2-chloro-3-pyridinyl)amino]-1-piperidinecarboxylic acid Et ester, which was further reacted with chlorosulfonyl isocyanate and then hydrolyzed to form 4-[(aminocarbonyl)(2-chloro-3-pyridinyl)amino]-1-piperidinecarboxylic acid Et ester. The intermediate formed above was treated with palladium diacetate and bis(diphenylphosphino)butane to form 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-1-piperidinecarboxylic acid Et ester, which was further treated with NaOH and then HCl to give the title compound as a final product.

IT 781649-09-0P


RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 1-piperidin-4-yl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one dihydrochloride)

RN 781649-09-0 CAPLUS


CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-2-oxo-1-(2,2,2-trifluoroethyl)-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.



IT 953077-35-5P
 RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP
 (Preparation)
 (preparation of 1-piperidin-4-yl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one
 dihydrochloride)
 RN 953077-35-5 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-2-oxo-
 1-(2,2,2-trifluoroethyl)-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-
 imidazo[4,5-b]pyridin-1-yl)-, compd. with ethanol, potassium salt (1:1:1)
 (CA INDEX NAME)
 CM 1
 CRN 781649-09-0
 CMF C26 H27 F5 N6 O3

Absolute stereochemistry.




CM 2
 CRN 64-17-5
 CMF C2 H6 O

H₃C—CH₂—OH

L5 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2007:1141392 CAPLUS Full-text
 DN 148:24343
 TI Potent, Orally Bioavailable Calcitonin Gene-Related Peptide Receptor Antagonists for the Treatment of Migraine: Discovery of N-[(3R,6S)-6-(2,3-Difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide (MK-0974)
 AU Paone, Daniel V.; Shaw, Anthony W.; Nguyen, Diem N.; Burgey, Christopher S.; Deng, James Z.; Kane, Stefanie A.; Koblan, Kenneth S.; Salvatore, Christopher A.; Mosser, Scott D.; Johnston, Victor K.; Wong, Bradley K.; Miller-Stein, Cynthia M.; Hershey, James C.; Graham, Samuel L.; Vacca, Joseph P.; Williams, Theresa M.
 CS Department of Medicinal Chemistry, Merck Research Laboratories, West Point, PA, 19486, USA
 SO Journal of Medicinal Chemistry (2007), 50(23), 5564-5567
 CODEN: JMCMAR; ISSN: 0022-2623
 PB American Chemical Society
 DT Journal
 LA English
 AB Calcitonin gene-related peptide (CGRP) has been implicated in the pathogenesis of migraine. Herein we describe optimization of CGRP receptor antagonists based on an earlier lead structure containing a (3R)-amino-(6S)-phenylcaprolactam core. Replacement of the phenylimidazolinone with an azabenzimidazolone gave stable derivs. with lowered serum shifts. Extensive SAR studies of the C-6 aryl moiety revealed the potency-enhancing effect of the 2,3-difluorophenyl group, and trifluoroethylation of the N-1 amide position resulted in improved oral bioavailabilities, ultimately leading to clin. candidate 38 (MK-0974).
 IT 959410-80-1
 RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (preparation of oral CGRP receptor antagonists for migraine therapy: MK-0974 as clin. candidate)
 RN 959410-80-1 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(3R,6S)-1-(cyclopropylmethyl)hexahydro-2-oxo-6-phenyl-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.



IT 959410-84-5P 959410-85-6P 959410-86-7P
 959410-87-8P 959410-88-9P 959410-89-0P

959410-90-3P 959410-91-4P 959410-92-5P
 959410-93-6P 959410-94-7P 959410-95-8P
 959410-96-9P 959410-97-0P 959410-98-1P
 959410-99-2P 959411-00-8P 959411-01-9P
 959411-02-0P 959411-03-1P 959411-04-2P
 959411-05-3P 959411-06-4P 959411-07-5P
 959411-08-6P 959411-09-7P 959411-10-0P
 959411-11-1P 959411-12-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)


(preparation of oral CGRP receptor antagonists for migraine therapy: MK-
 0974

as clin. candidate)

RN 959410-84-5 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-
 [(3R,6S)-hexahydro-2-oxo-6-phenyl-1H-azepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 959410-85-6 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-
 [(3R)-hexahydro-6-(4-hydroxyphenyl)-2-oxo-1H-azepin-3-yl]- (CA INDEX
 NAME)


Absolute stereochemistry.



RN 959410-86-7 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-
 [(3R)-hexahydro-2-oxo-6-(2-pyridinyl)-1H-azepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 959410-87-8 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-[(3R)-hexahydro-2-oxo-6-(3-pyridinyl)-1H-azepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 959410-88-9 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-[(3R)-hexahydro-2-oxo-6-(3-thienyl)-1H-azepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 959410-89-0 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-[(3R)-hexahydro-6-(2-methoxyphenyl)-2-oxo-1H-azepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 959410-90-3 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-[(3R)-hexahydro-6-(4-methylphenyl)-2-oxo-1H-azepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 959410-91-4 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-[(3R)-hexahydro-6-(1-methylethyl)-2-oxo-1H-azepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 959410-92-5 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-

[(3R)-hexahydro-2-oxo-6-(phenylmethyl)-1H-azepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 959410-93-6 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-[(3R)-6-(2-fluorophenyl)hexahydro-2-oxo-1H-azepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 959410-94-7 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-[(3R)-6-(3-fluorophenyl)hexahydro-2-oxo-1H-azepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 959410-95-8 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-
[(3R,6S)-6-(2-fluorophenyl)hexahydro-2-oxo-1H-azepin-3-yl]- (CA INDEX
NAME)


Absolute stereochemistry.



RN 959410-96-9 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-
[(3R,6S)-6-(3-fluorophenyl)hexahydro-2-oxo-1H-azepin-3-yl]- (CA INDEX
NAME)


Absolute stereochemistry.



RN 959410-97-0 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-2-oxo-
1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (CA INDEX
NAME)


Absolute stereochemistry.



RN 959410-98-1 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-1-(2-methoxyethyl)-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 959410-99-2 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-1-(2-hydroxyethyl)-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 959411-00-8 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-2-oxo-

1-[2-(trifluoromethoxy)ethyl]-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 959411-01-9 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)-1-[2-(dimethylamino)ethyl]hexahydro-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 959411-02-0 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-1-[2-(4-morpholinyl)ethyl]-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 959411-03-1 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-2-oxo-1-(2-pyridinylmethyl)-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 959411-04-2 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-1-[2-(methylthio)ethyl]-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 959411-05-3 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-1-[2-(methylsulfinyl)ethyl]-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 959411-06-4 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-1-[2-(methylsulfonyl)ethyl]-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 959411-07-5 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-1-(cyclopropylmethyl)-6-(2,3-

difluorophenyl)hexahydro-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 959411-08-6 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-1-methyl-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 959411-09-7 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)-1-ethylhexahydro-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 959411-10-0 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)-1-(2-fluoroethyl)hexahydro-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 959411-11-1 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-1-(2,2-difluoroethyl)-6-(2,3-difluorophenyl)hexahydro-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 959411-12-2 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-2-oxo-1-(2,2,2-trifluoroethyl)-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.



IT 783367-85-1 862280-81-7 862280-90-8


RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(preparation of oral CGRP receptor antagonists for migraine therapy: MK-0974 as clin. candidate)

RN 783367-85-1 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-1-(cyclopropylmethyl)hexahydro-2-oxo-6-phenyl-1H-azepin-3-yl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 862280-81-7 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-1-(cyclopropylmethyl)hexahydro-2-oxo-6-phenyl-1H-azepin-3-yl]-4-(2,5-dihydro-5-oxo-3-phenyl-1H-1,2,4-triazol-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 862280-90-8 CAPLUS


CN 1-Piperidinecarboxamide, N-[(3R,6S)-1-(cyclopropylmethyl)hexahydro-2-oxo-6-phenyl-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)-
(CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 9 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2007:862437 CAPLUS Full-text
 DN 147:406673
 TI Caprolactams as potent CGRP receptor antagonists for the treatment of migraine
 AU Shaw, Anthony W.; Paone, Daniel V.; Nguyen, Diem N.; Stump, Craig A.; Burgey, Christopher S.; Mosser, Scott D.; Salvatore, Christopher A.; Rutledge, Ruth Z.; Kane, Stefanie A.; Koblan, Kenneth S.; Graham, Samuel L.; Vacca, Joeseeph P.; Williams, Theresa M.
 CS Department of Medicinal Chemistry, Merck Research Laboratories, West Point, PA, 19486, USA
 SO Bioorganic & Medicinal Chemistry Letters (2007), 17(17), 4795-4798
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier Ltd.
 DT Journal
 LA English
 OS CASREACT 147:406673
 GI



I

AB Calcitonin gene-related peptide (CGRP) has been implicated in the pathogenesis of migraine. Replacements for the benzodiazepine core of an earlier lead structure including 5-, 6-, and 7-membered lactams were explored. Within the 7-membered ring scaffold, Ph substitution at various positions afforded the potent (3R)-amino-(6S)-Ph caprolactam template. The phenylimidazolinone privileged structure gave addnl. potency enhancements, as I showed good potency in both CGRP binding ($K_i = 2$ nM) and cAMP ($IC_{50} = 4$ nM) assays and was orally bioavailable in rats (27%).
 IT 783367-79-3P 783367-82-8P 783367-85-1P
 862280-81-7P 862280-90-8P 862280-99-7P
 862281-00-3P 862281-15-0P 862281-16-1P
 951024-10-5P 951024-12-7P 951024-13-8P
 951024-14-9P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation of caprolactams as potent calcitonin gene-related peptide receptor antagonists for the treatment of migraine)
 RN 783367-79-3 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(3R,7R)-1-(cyclopropylmethyl)hexahydro-2-oxo-7-phenyl-1H-azepin-3-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 783367-82-8 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-1-(cyclopropylmethyl)hexahydro-2-oxo-6-phenyl-1H-azepin-3-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 783367-85-1 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-1-(cyclopropylmethyl)hexahydro-2-oxo-6-phenyl-1H-azepin-3-yl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 862280-81-7 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-1-(cyclopropylmethyl)hexahydro-2-oxo-6-phenyl-1H-azepin-3-yl]-4-(2,5-dihydro-5-oxo-3-phenyl-1H-1,2,4-triazol-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 862280-90-8 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-1-(cyclopropylmethyl)hexahydro-2-oxo-6-phenyl-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 862280-99-7 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,5R)-1-(cyclopropylmethyl)hexahydro-2-oxo-5-phenyl-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 862281-00-3 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,5S)-1-(cyclopropylmethyl)hexahydro-2-oxo-5-phenyl-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 862281-15-0 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,5R)-1-(cyclopropylmethyl)hexahydro-2-oxo-5-phenyl-1H-azepin-3-yl]-4-(2,5-dihydro-5-oxo-3-phenyl-1H-1,2,4-triazol-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 862281-16-1 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,5S)-1-(cyclopropylmethyl)hexahydro-2-oxo-5-phenyl-1H-azepin-3-yl]-4-(2,5-dihydro-5-oxo-3-phenyl-1H-1,2,4-triazol-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 951024-10-5 CAPLUS

CN 1H-Azepine-1-carboxylic acid, 3-[[[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]carbonyl]amino]hexahydro-2-oxo-7-phenyl-, 1,1-dimethylethyl ester, (3R,7S)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 951024-12-7 CAPLUS

CN 1H-Azepine-1-carboxylic acid, 3-[[[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]carbonyl]amino]hexahydro-2-oxo-7-phenyl-, 1,1-dimethylethyl ester, (3S,7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 951024-13-8 CAPLUS

CN 1H-Azepine-1-carboxylic acid, 3-[[[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]carbonyl]amino]hexahydro-2-oxo-7-phenyl-, 1,1-dimethylethyl ester, (3R,7R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 951024-14-9 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3S,6R)-1-(cyclopropylmethyl)hexahydro-2-oxo-6-phenyl-1H-azepin-3-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (CA INDEX NAME)

Absolute stereochemistry.




IT 783367-84-0P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of caprolactams as potent calcitonin gene-related peptide receptor antagonists for the treatment of migraine)

RN 783367-84-0 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6R)-1-(cyclopropylmethyl)hexahydro-2-oxo-6-phenyl-1H-azepin-3-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-, rel- (CA INDEX NAME)


Relative stereochemistry.



RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 10 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2007:301977 CAPLUS Full-text
 DN 146:501334
 TI Enantioselective synthesis of aminobenzazepinones
 AU Prasad, C. V. C.; Mercer, Stephen E.; Dubowchik, Gene M.; Macor, John E.
 CS Discovery Chemistry, Bristol-Myers Squibb Pharmaceutical Research
 Institute, Wallingford, CT, USA
 SO Tetrahedron Letters (2007), 48(15), 2661-2665
 CODEN: TELEAY; ISSN: 0040-4039
 PB Elsevier Ltd.
 DT Journal
 LA English
 OS CASREACT 146:501334
 AB Enantioselective synthesis of constrained trans-aminobenzazepinone utilizing
 palladium-mediated Jeffery-Heck reaction and rhodium(II)-catalyzed asym.
 hydrogenation as key steps are described. Diverse functional groups such as
 alkyl, aryl, basic, or amino acid moieties were introduced with minimal
 racemization.
 IT 936572-65-SP
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (asym. synthesis of aminobenzazepinones as dipeptide mimetics via
 palladium-mediated Jeffery-Heck reaction and rhodium-catalyzed asym.
 hydrogenation)
 RN 936572-65-5 CAPLUS
 CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[(4S)-
 2-(2,2-dimethylpropyl)-2,3,4,5-tetrahydro-8-hydroxy-3-oxo-1H-2-benzazepin-
 4-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2006:1070147 CAPLUS Full-text
 DN 145:419134
 TI Constrained indazoloazepinones and related compounds as CGRP-receptor antagonists and their preparation, pharmaceutical compositions, and use for treatment of migraine
 IN Chaturvedula, Prasad V.; Mercer, Stephen E.; Fang, Haiquan
 PA USA
 SO U.S. Pat. Appl. Publ., 140pp., Cont.-in-part of U.S. Ser. No. 247,697.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2006229447	A1	20061012	US 2006-417326	20060503
	US 2006094707	A1	20060504	US 2005-247697	20051011
	IN 2007DN03133	A	20070831	IN 2007-DN3133	20070426
	WO 2007130860	A2	20071115	WO 2007-US67617	20070427
	WO 2007130860	A3	20080221		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW:				
	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
PRAI	US 2004-624655P	P	20041103		
	US 2005-678099P	P	20050505		
	US 2005-247697	A2	20051011		
	WO 2005-US36859	W	20051012		
	US 2006-417326	A	20060503		
OS	MARPAT 145:419134				
GI					

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention encompasses constrained bicyclic and tricyclic CGRP-receptor antagonists of formula I, methods for identifying them, pharmaceutical compns. comprising them, and methods for their use in therapy for treatment of migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors. Compds. I [R1 = (halo)alkyl, alkenyl, cycloalkyl, etc.; R2 = H, halo, OH, alkyl, etc.; R3 = H, OH, halo, alkyl, or alkenyl; or R2R3 together are CHNNR5; R4 = H, halo, alkyl, or alkenyl; R5 = H or alkyl; R6 = H, alkyl, or spiro[imidazolidinedione-cycloalkaphenyl]; or NR5R6 taken together = (un)substituted 6-membered aza-cycle, or spiro-substituted piperidine; X-Y = aminocarbonyl, oxycarbonyl, methylenecarbonyl, ethylene, or amino(cyano)iminomethyl; n = 0-1; and their pharmaceutically acceptable salts or solvates thereof] were prepared Thus,

compound II was prepared by substitution of (9-benzyl-4-chloro-8-oxo-3,6,7,8,9,10-hexahydro-2,3,9-triaza-(R)-cyclohepta[*e*]inden-7-yl)carbamic acid benzyl ester with 4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)piperidine. Compds. I were evaluated for their CGRP receptor binding activity. It was determined that most of the invention compds. exhibited CGRP receptor activity. For example, II was found to have an IC₅₀ value between 0.1-10 nM against CGRP receptors and for cAMP functions. Compds. I are claimed to be useful for treatment migraine.


IT 885607-16-9P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate and intermediate; preparation of constrained indazoloazepinones and related compds. as CGRP-receptor antagonists for treatment of migraine)

RN 885607-16-9 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-(2,3,4,5-tetrahydro-8-hydroxy-2-methyl-3-oxo-1H-2-benzazepin-4-yl)- (CA INDEX NAME)



IT 885606-79-1P 885606-81-5P 885606-83-7P
 885606-84-8P 885606-86-0P 885606-88-2P
 885606-90-6P 885606-94-0P 885606-95-1P
 885606-96-2P 885606-97-3P 885606-99-5P
 885607-00-1P 885607-01-2P 885607-02-3P
 885607-03-4P 885607-04-5P 885607-05-6P
 885607-06-7P 885607-08-9P 885607-10-3P
 885607-12-5P 885607-14-7P 885607-15-8P
 885607-17-0P 885607-18-1P 885607-20-5P
 885607-21-6P 885607-22-7P 885607-23-8P
 885607-24-9P 885607-26-1P 885607-27-2P
 885607-28-3P 885607-29-4P 885607-31-8P
 885607-32-9P 885607-33-0P 885607-34-1P
 885607-35-2P 885607-36-3P 885607-37-4P
 885607-38-5P 885607-39-6P 885607-40-9P
 885607-41-0P 885607-46-5P 885607-47-6P
 885607-48-7P 885607-50-1P 885607-51-2P
 885607-59-0P 885607-61-4P 885607-62-5P
 885607-63-6P 885607-64-7P 885607-72-7P
 885607-73-8P 885607-74-9P 885607-75-0P
 885607-78-3P 885607-79-4P 885607-80-7P
 885607-81-8P 885607-82-9P 885607-83-0P
 885607-84-1P 885607-85-2P 885607-86-3P
 885607-87-4P 885607-88-5P 885607-89-6P
 885607-90-9P 885607-91-0P 885607-92-1P
 885607-93-2P 885607-94-3P 885607-95-4P
 885607-96-5P 885607-97-6P 885607-98-7P
 885607-99-8P 885608-00-4P 885608-01-5P

885608-02-6P 885608-03-7P 885608-04-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of constrained indazoloazepinones and related compds. as CGRP-receptor antagonists for treatment of migraine)

RN 885606-79-1 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[(7R)-3,6,7,8,9,10-hexahydro-8-oxo-9-(phenylmethyl)pyrazolo[3,4-i][2]benzazepin-7-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 885606-81-5 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[(7R)-3,6,7,8,9,10-hexahydro-9-methyl-8-oxopyrazolo[3,4-i][2]benzazepin-7-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 885606-83-7 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[(7R)-3,6,7,8,9,10-hexahydro-8-oxo-9-[2-(1-piperidinyl)ethyl]pyrazolo[3,4-i][2]benzazepin-7-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 885606-84-8 CAPLUS

CN 1-Piperidinecarboxamide, 4-((1R,4R)-4-((2-(1-piperidin-1-ylethyl)-1H-pyrazolo[3,4-i][2]benzazepin-7-yl)-2-oxo-3,6,7,8,9,10-hexahydroquinazolin-2-yl)-1,4-dihydroquinazolin-2(1H)-one (CA INDEX NAME)


Absolute stereochemistry.



RN 885606-86-0 CAPLUS


CN 1-Piperidinecarboxamide, 4-((1R,4R)-4-((2-(1-piperidin-1-ylethyl)-1H-pyrazolo[3,4-i][2]benzazepin-7-yl)-2-oxo-3,6,7,8,9,10-hexahydroquinazolin-2-yl)-1,4-dihydroquinazolin-2(1H)-one (CA INDEX NAME)

Absolute stereochemistry.



RN 885606-88-2 CAPLUS


CN 6H-Pyrazolo[3,4-g]quinolin-6-one, 7-[2-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-oxoethyl]-5-(2,2-dimethylpropyl)-1,5,7,8-tetrahydro- (CA INDEX NAME)



RN 885606-90-6 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[(7R)-3,6,7,8,9,10-hexahydro-9-[2-(4-morpholinyl)ethyl]-8-oxopyrazolo[3,4-i][2]benzazepin-7-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 885606-94-0 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[(7R)-3,6,7,8,9,10-hexahydro-8-oxo-9-[(1S)-1-phenylethyl]pyrazolo[3,4-i][2]benzazepin-7-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 885606-95-1 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[(7R)-3,6,7,8,9,10-hexahydro-8-oxo-9-[(1R)-1-phenylethyl]pyrazolo[3,4-i][2]benzazepin-7-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 885606-96-2 CAPLUS

CN 1-Piperidinecarboxamide, N-[(7R)-4-chloro-3,6,7,8,9,10-hexahydro-8-oxo-9-(phenylmethyl)pyrazolo[3,4-i][2]benzazepin-7-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885606-97-3 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[(7R)-3,6,7,8,9,10-hexahydro-8-oxo-9-[[4-(trifluoromethyl)phenyl]methyl]pyrazolo[3,4-i][2]benzazepin-7-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 885606-99-5 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[(7R)-3,6,7,8,9,10-hexahydro-9-(1-methylethyl)-8-oxopyrazolo[3,4-i][2]benzazepin-7-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-00-1 CAPLUS

CN 1-Piperidinecarboxamide, 4-[(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[(7R)-9-(3,3-dimethylbutyl)-3,6,7,8,9,10-hexahydro-8-oxopyrazolo[3,4-i][2]benzazepin-7-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-01-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(7R)-7-[[[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]carbonyl]amino]-6,7,8,10-tetrahydro-8-oxopyrazolo[3,4-i][2]benzazepin-9(3H)-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-02-3 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[(7R)-3,6,7,8,9,10-hexahydro-8-oxo-9-(4-piperidinyl)pyrazolo[3,4-i][2]benzazepin-7-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-03-4 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 7-[2-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-oxoethyl]-9-(2,2-dimethylpropyl)-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-04-5 CAPLUS

CN 1-Piperidinecarboxamide, N-[(7R)-4-chloro-9-(2,2-dimethylpropyl)-3,6,7,8,9,10-hexahydro-8-oxopyrazolo[3,4-i][2]benzazepin-7-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-05-6 CAPLUS


CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-oxoethyl]-9-(2,2-dimethylpropyl)-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 885607-06-7 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[9-(2,2-dimethylpropyl)-3,6,7,8,9,10-hexahydro-8-oxopyrazolo[3,4-i][2]benzazepin-7-yl]- (CA INDEX NAME)




RN 885607-08-9 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[3,6,7,8,9,10-hexahydro-9-(2-methylpropyl)-8-oxopyrazolo[3,4-i][2]benzazepin-7-yl]- (CA INDEX NAME)




RN 885607-10-3 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[3,6,7,8,9,10-hexahydro-8-oxo-9-[2-(4-pyridinyl)ethyl]pyrazolo[3,4-i][2]benzazepin-7-yl]- (CA INDEX NAME)




RN 885607-12-5 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[3,6,7,8,9,10-hexahydro-8-oxo-9-(4-pyridinylmethyl)pyrazolo[3,4-i][2]benzazepin-7-yl]- (CA INDEX NAME)




RN 885607-14-7 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-(3,6,7,8,9,10-hexahydro-4,9-dimethyl-8-oxopyrazolo[3,4-i][2]benzazepin-7-yl)- (CA INDEX NAME)




RN 885607-15-8 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[2,3,4,5-tetrahydro-2-methyl-3-oxo-8-(phenylmethoxy)-1H-2-benzazepin-4-yl]- (CA INDEX NAME)




RN 885607-17-0 CAPLUS

CN 1-Piperidinecarboxamide, N-(7,9-dichloro-2,3,4,5-tetrahydro-8-hydroxy-2-methyl-3-oxo-1H-2-benzazepin-4-yl)-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (CA INDEX NAME)



RN 885607-18-1 CAPLUS


CN 1-Piperidinecarboxamide, N-(7,9-dibromo-2,3,4,5-tetrahydro-8-hydroxy-2-methyl-3-oxo-1H-2-benzazepin-4-yl)-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (CA INDEX NAME)



RN 885607-20-5 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 7-[2-[4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)-1-piperidinyl]-2-oxoethyl]-9-(2,2-dimethylpropyl)-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-21-6 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[(6R)-1,5,6,7,8,9-hexahydro-7-oxo-8-(phenylmethyl)pyrazolo[4,3-h][2]benzazepin-6-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-22-7 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 7-[2-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(phenylmethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-23-8 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 9-(2,2-dimethylpropyl)-7-[2-[4-(8-fluoro-1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-24-9 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-9-(2,2-dimethylpropyl)-7-[2-[4-(8-fluoro-1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-26-1 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 7-[2-[4-(1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-9-(2,2-dimethylpropyl)-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-27-2 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-9-(2,2-dimethylpropyl)-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-28-3 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)-1-piperidinyl]-2-oxoethyl]-9-(2,2-dimethylpropyl)-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-29-4 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-[2,3-dihydro-2-oxo-4-(2-pyridinyl)-1H-imidazol-1-yl]-1-piperidinyl]-2-oxoethyl]-9-(2,2-dimethylpropyl)-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-31-8 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-9-(2,2-dimethylpropyl)-7-[2-[4-(8-fluoro-1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-32-9 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(3,4-dihydro-3-oxo-2-quinoxalinyloxy)-1-piperidinyl]-2-oxoethyl]-9-(2,2-dimethylpropyl)-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-33-0 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(4-pyridinylmethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-34-1 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(8-fluoro-1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(4-pyridinylmethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-35-2 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(8-fluoro-1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(4-pyridinylmethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-36-3 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(4-pyridinylmethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-37-4 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(4-pyridinylmethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-38-5 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(1H-imidazol-2-ylmethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-39-6 CAPLUS

CN 1-Piperidinecarboxamide, N-[(4R)-8-amino-2,3,4,5-tetrahydro-7-methyl-3-oxo-2-(phenylmethyl)-1H-2-benzazepin-4-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-40-9 CAPLUS

CN 1-Piperidinecarboxamide, N-[(4R)-8-amino-2,3,4,5-tetrahydro-9-methyl-3-oxo-2-(phenylmethyl)-1H-2-benzazepin-4-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-41-0 CAPLUS

CN 1-Piperidinecarboxamide, N-[(7R)-3,6,7,8,9,10-hexahydro-8-oxo-9-(phenylmethyl)pyrazolo[3,4-i][2]benzazepin-7-yl]-4-(1,2,3,4-tetrahydro-2-oxo-3-quinoliny)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-46-5 CAPLUS

CN 1-Piperidinecarboxamide, N-[(7R)-9-(1-acetyl-4-piperidiny)-3,6,7,8,9,10-hexahydro-8-oxopyrazolo[3,4-i][2]benzazepin-7-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-47-6 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[(7R)-3,6,7,8,9,10-hexahydro-8-oxo-9-(3-pyrrolidinyl)pyrazolo[3,4-i][2]benzazepin-7-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-48-7 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 7-[2-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]ethyl]-9-(2,2-dimethylpropyl)-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-50-1 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 7-[2-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-oxoethyl]-9-(2,2-dimethylpropyl)-6,7,9,10-tetrahydro-, (7R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-51-2 CAPLUS

CN 1-Piperidinecarboxamide, N-[(7R)-9-(2,2-dimethylpropyl)-3,6,7,8,9,10-hexahydro-8-oxopyrazolo[3,4-i][2]benzazepin-7-yl]-4-(1,2,3,4-tetrahydro-2-oxo-3-quinolinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-59-0 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-61-4 CAPLUS

CN 2,4-Imidazolidinedione, 3-[1-[2-[(7S)-4-chloro-9-(2,2-dimethylpropyl)-3,6,7,8,9,10-hexahydro-8-oxopyrazolo[3,4-i][2]benzazepin-7-yl]acetyl]-4-piperidinyl]-1-phenyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-62-5 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(1,4-dihydro-2-oxopyrido[2,3-d]pyrimidin-3(2H)-yl)-1-piperidinyl]-2-oxoethyl]-9-(2,2-dimethylpropyl)-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-63-6 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(1,2-dihydro-2-oxo-1,8-naphthyridin-3-yl)-1-piperidinyl]-2-oxoethyl]-9-(2,2-dimethylpropyl)-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-64-7 CAPLUS


CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(1,2-dihydro-2-oxo-1,6-naphthyridin-3-yl)-1-piperidinyl]-2-oxoethyl]-9-(2,2-dimethylpropyl)-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 885607-72-7 CAPLUS


CN 1-Piperidinecarboximidamide, N-cyano-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N'-[9-(2,2-dimethylpropyl)-3,6,7,8,9,10-hexahydro-8-oxopyrazolo[3,4-i][2]benzazepin-7-yl]- (CA INDEX NAME)



RN 885607-73-8 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(1,2-dihydro-2-oxo-1,8-naphthyridin-3-yl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-74-9 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-75-0 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(8-fluoro-1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-78-3 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-bromo-7-[2-[4-(1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-9-(2,2-dimethylpropyl)-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-79-4 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-bromo-9-(2,2-dimethylpropyl)-7-[2-[4-(8-fluoro-1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-80-7 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-bromo-7-[2-[4-(1,2-dihydro-2-oxo-1,8-naphthyridin-3-yl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-81-8 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-bromo-7-[2-[4-(1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-82-9 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-bromo-7-[2-[4-(8-fluoro-1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-83-0 CAPLUS

CN 1-Piperidinecarboximidamide, N-[(7R)-4-chloro-9-(2,2-dimethylpropyl)-3,6,7,8,9,10-hexahydro-8-oxopyrazolo[3,4-i][2]benzazepin-7-yl]-N'-cyano-4-(1,2-dihydro-2-oxo-3-quinolinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-84-1 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 7-[2-[4-(1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-9-(2,2-dimethylpropyl)-6,7,9,10-tetrahydro-4-methyl-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-85-2 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 9-(2,2-dimethylpropyl)-7-[2-[4-(8-fluoro-1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-4-methyl-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-86-3 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 7-[2-[4-(1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-4-methyl-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-87-4 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 7-[2-[4-(8-fluoro-1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-4-methyl-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-88-5 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 7-[2-[4-(1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-9-(2,2-dimethylpropyl)-6,7,9,10-tetrahydro-4-(1-methylethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-89-6 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 9-(2,2-dimethylpropyl)-7-[2-[4-(8-fluoro-1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-4-(1-methylethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-90-9 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 7-[2-[4-(1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-4-(1-methylethyl)-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-91-0 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 7-[2-[4-(8-fluoro-1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-4-(1-methylethyl)-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-92-1 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 7-[2-[4-(1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-4-(1-methylethenyl)-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-93-2 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 7-[2-[4-(8-fluoro-1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-4-(1-methylethenyl)-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-94-3 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-ethyl-7-[2-[4-(8-fluoro-1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-95-4 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-bromo-9-(cyclopropylmethyl)-7-[2-[4-(1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-96-5 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-bromo-9-(cyclopropylmethyl)-7-[2-[4-(8-fluoro-1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-97-6 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-bromo-7-[2-[4-(1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(2-methoxyethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-98-7 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-bromo-7-[2-[4-(8-fluoro-1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(2-methoxyethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-99-8 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(6,7-difluoro-1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-9-(2,2-dimethylpropyl)-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885608-00-4 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(7-chloro-1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-9-(2,2-dimethylpropyl)-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885608-01-5 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(8-chloro-1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-9-(2,2-dimethylpropyl)-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885608-02-6 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-9-(2,2-dimethylpropyl)-7-[2-[4-(5-fluoro-1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885608-03-7 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-9-(2,2-dimethylpropyl)-7-[2-[4-(7-fluoro-1,2-dihydro-2-oxo-1,8-naphthyridin-3-yl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885608-04-8 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-9-(2,2-dimethylpropyl)-7-[2-[4-(7-fluoro-1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)

Absolute stereochemistry.



IT 885608-26-4P 885608-96-8P 885609-01-8P

885609-11-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of constrained indazoloazepinones and related compds. as CGRP-receptor antagonists for treatment of migraine)

RN 885608-26-4 CAPLUS

CN 1-Piperidinecarboxamide, N-[(7R)-3-acetyl-3,6,7,8,9,10-hexahydro-8-oxo-9-(phenylmethyl)pyrazolo[3,4-i][2]benzazepin-7-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885608-96-8 CAPLUS

CN Carbamic acid, N-[(4R)-4-[[[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]carbonyl]amino]-2,3,4,5-tetrahydro-7-methyl-3-oxo-2-(phenylmethyl)-1H-2-benzazepin-8-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 885609-01-8 CAPLUS

CN Carbamic acid, N-[(4R)-4-[[[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]carbonyl]amino]-2,3,4,5-tetrahydro-9-methyl-3-oxo-2-(phenylmethyl)-1H-2-benzazepin-8-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 885609-11-0 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 3-[(7R)-7-[[[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]carbonyl]amino]-6,7,8,10-tetrahydro-8-oxopyrazolo[3,4-i][2]benzazepin-9(3H)-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



IT 912462-55-6P 912462-57-8P 912462-59-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of constrained indazoloazepinones and related compds. as CGRP-receptor antagonists for treatment of migraine)

RN 912462-55-6 CAPLUS

CN 1-Piperidinecarboximidamide, N-[(7R)-4-chloro-3,6,7,8,9,10-hexahydro-8-oxo-9-(2,2,2-trifluoroethyl)pyrazolo[3,4-i][2]benzazepin-7-yl]-N'-cyano-4-(1,2-dihydro-2-oxo-3-quinolinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 912462-57-8 CAPLUS

CN 1-Piperidinecarboximidamide, N-[(7R)-4-chloro-3,6,7,8,9,10-hexahydro-8-oxo-9-(2,2,2-trifluoroethyl)pyrazolo[3,4-i][2]benzazepin-7-yl]-N'-cyano-4-(8-fluoro-1,2-dihydro-2-oxo-3-quinolinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 912462-59-0 CAPLUS




CN 1-Piperidinecarboxylic acid, 4-(1,2-dihydro-2-oxo-3-quinolinyl)-,
(7R)-4-chloro-3,6,7,8,9,10-hexahydro-8-oxo-9-(2,2,2-
trifluoroethyl)pyrazolo[3,4-i][2]benzazepin-7-yl ester (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2006:977832 CAPLUS Full-text
 DN 145:377333
 TI Preparation of oxoimidazopyridylpiperidinylcarbonylaminopyridones and related compounds as calcitonin gene-related peptide (CGRP) receptor antagonists
 IN Paone, Daniel, V.; Nguyen, Diem, N.; Shaw, Anthony, W.; Burgey, Christopher, S.; Tucker, Thomas, J.; Graham, Samuel, L.
 PA Merck & Co., Inc., USA
 SO PCT Int. Appl., 127pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006099268	A2	20060921	WO 2006-US8859	20060314
	WO 2006099268	A3	20071122		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
	AU 2006223236	A1	20060921	AU 2006-223236	20060314
	CA 2599925	A1	20060921	CA 2006-2599925	20060314
	EP 1861399	A2	20071205	EP 2006-748359	20060314
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU			
	IN 2007CN03733	A	20071123	IN 2007-CN3733	20070827
PRAI	US 2005-661565P	P	20050314		
	WO 2006-US8859	W	20060314		
OS	MARPAT 145:377333				
GI					



AB Title compds. [I; Z = Q1, Q2; A = N, CR2; B = O, S; R1, R2, R7a, R7b = H, (substituted) alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl,

heteroaryl; R1R2, R2R2 = atoms to form rings; R3 = H, F, cyano, CO2R4, (substituted) alkyl; W = O, NR4, C(R4)2; X = C, S; Y = O, (R4)2, NCN, NCONH2, O2; J = bond, C(R6)2, O, NR6; V = bond, C(R6)2, O, S, SO, SO2, NR6, etc.; GL = N, NC(R6)2, C:CR6, CN, CR6, etc.; Q = CR7a, C(R7a)2, CO, S, SO, SO2, N, NR7a; T = CR7b, C(R7b)2, CO, S, SO, SO2, N, NR7b; with provisos], were prepared for treatment of headache, migraine, and cluster headache. Thus, N-(5-bromo-1-methyl-2-oxo-1,2-dihydropyridin-3-yl)-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide (preparation given), phenylboronic acid, diisopropylamine, Pd(OAc)2, and 3,3',3''-phosphinidynetris(benzenesulfonic acid) trisodium salt were heated in DMF/H2O at 80° for 18 h to give N-(1-methyl-2-oxo-5-phenyl-1,2-dihydropyridin-3-yl)-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide as the trifluoroacetate. I generally antagonized CGRP receptors with Ki or IC50 values of ≤50 μM.


IT 910543-23-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(claimed compound; preparation of oxoimidazopyridylpiperidinylcarbonylaminopyridones and related compds. as CGRP antagonists)

RN 910543-23-6 CAPLUS

CN 1-Piperidinecarboxamide, N-[5-(2,3-difluorophenyl)-1,2-dihydro-2-oxo-3-pyridinyl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)



L5 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2006:409732 CAPLUS Full-text
 DN 144:450702
 TI Constrained indazoloazepinones and related compounds as CGRP-receptor antagonists and their preparation, pharmaceutical compositions, and use for treatment of migraine
 IN Chaturvedula, Prasad V.; Mercer, Stephen E.; Fang, Haiquan
 PA USA
 SO U.S. Pat. Appl. Publ., 112 pp.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2006094707	A1	20060504	US 2005-247697	20051011
	AU 2005305245	A1	20060518	AU 2005-305245	20051012
	CA 2586370	A1	20060518	CA 2005-2586370	20051012
	WO 2006052378	A1	20060518	WO 2005-US36859	20051012
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	EP 1809633	A1	20070725	EP 2005-808743	20051012
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, MK, YU				
	CN 101094854	A	20071226	CN 2005-80045264	20051012
	US 2006229447	A1	20061012	US 2006-417326	20060503
	IN 2007DN03133	A	20070831	IN 2007-DN3133	20070426
	MX 200705119	A	20070704	MX 2007-5119	20070427
	NO 2007002188	A	20070719	NO 2007-2188	20070427
	KR 2007085647	A	20070827	KR 2007-712438	20070601
PRAI	US 2004-624655P	P	20041103		
	US 2005-678099P	P	20050505		
	US 2005-247697	A	20051011		
	WO 2005-US36859	W	20051012		
OS	MARPAT 144:450702				
GI					

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention encompasses constrained bicyclic and tricyclic CGRP-receptor antagonists of formula I, methods for identifying them, pharmaceutical compns. comprising them, and methods for their use in therapy for treatment of migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of


which can be effected by the antagonism of CGRP-receptors. Comps. of formula I, wherein R1 is C1-6 (halo)alkyl, C2-6 alkenyl, C3-7 cycloalkyl, C5-7 cyclalkenyl, C1-6(C3-7 cycloalkenyl)alkyl, C1-6(C1-6alkoxyl)alkyl, C1-6(hetero)arylalkyl, C1-6(NH2)alkyl and derivs., NH-pyrrolidinyl and derivs., or NH-piperidinyl and derivs.; R2 is H, halo, OH, C1-6 alkyl, C2-6 alkenyl, BnO, or NH2 and derivs.; R3 is H, OH, halo, C1-6 alkyl, or C2-6 alkenyl; or R2R3 together are CHNNR5; R4 is H, halo, C1-6 alkyl, or C2-6 alkenyl; R5 is H or C1-6 alkyl; R6 is H, C1-6 alkyl, or spiro[imidazolidinedione-cycloalkaphenyl]; or NR5R6 taken together is (un)substituted 6-membered aza-cycle, or spiro-substituted piperidine; X-Y is aminocarbonyl, oxycarbonyl, methylenecarbonyl, ethylene, or amino(cyano)iminomethyl; n is 0 or 1; and their pharmaceutically acceptable salts or solvates thereof are claimed. Example compound II was prepared by substitution of (9-benzyl-4-chloro-8-oxo-3,6,7,8,9,10-hexahydro-2,3,9-triaza-(R)-cyclohepta[e]inden-7-yl)carbamic acid benzyl ester with 4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)piperidine. All the invention compds. were evaluated for their CGRP receptor binding activity. From the assay, it was determined that most of the invention compds. exhibited CGRP receptor activity. Example compound II were found to have an IC50 value between 0.1-10 nM against CGRP receptors and for cAMP functions. These compds. are claimed to be useful for treatment migraine.

IT 885607-16-9P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate and intermediate; preparation of constrained indazoloazepinones and related compds. as CGRP-receptor antagonists and useful for treatment of migraine)

RN 885607-16-9 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-(2,3,4,5-tetrahydro-8-hydroxy-2-methyl-3-oxo-1H-2-benzazepin-4-yl)- (CA INDEX NAME)



IT 885606-79-1P 885606-81-5P 885606-83-7P
885606-84-8P 885606-86-0P 885606-88-2P
885606-90-6P 885606-94-0P 885606-95-1P
885606-96-2P 885606-97-3P 885606-99-5P
885607-00-1P 885607-01-2P 885607-02-3P
885607-03-4P 885607-04-5P 885607-05-6P
885607-06-7P 885607-08-9P 885607-10-3P
885607-12-5P 885607-14-7P 885607-15-8P
885607-17-0P 885607-18-1P 885607-20-5P
885607-21-6P 885607-22-7P 885607-23-8P
885607-24-9P 885607-26-1P 885607-27-2P
885607-28-3P 885607-29-4P 885607-31-8P
885607-32-9P 885607-33-0P 885607-34-1P
885607-35-2P 885607-36-3P 885607-37-4P
885607-38-5P 885607-39-6P 885607-40-9P
885607-41-0P 885607-46-5P 885607-47-6P

885607-48-7P 885607-50-1P 885607-51-2P
 885607-59-0P 885607-61-4P 885607-62-5P
 885607-63-6P 885607-64-7P 885607-72-7P
 885607-73-8P 885607-74-9P 885607-75-0P
 885607-78-3P 885607-79-4P 885607-80-7P
 885607-81-8P 885607-82-9P 885607-83-0P
 885607-84-1P 885607-85-2P 885607-86-3P
 885607-87-4P 885607-88-5P 885607-89-6P
 885607-90-9P 885607-91-0P 885607-92-1P
 885607-93-2P 885607-94-3P 885607-95-4P
 885607-96-5P 885607-97-6P 885607-98-7P
 885607-99-8P 885608-00-4P 885608-01-5P
 885608-02-6P 885608-03-7P 885608-04-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of constrained indazoloazepinones and related compds. as CGRP-receptor antagonists and useful for treatment of migraine)

RN 885606-79-1 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[(7R)-3,6,7,8,9,10-hexahydro-8-oxo-9-(phenylmethyl)pyrazolo[3,4-i][2]benzazepin-7-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 885606-81-5 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[(7R)-3,6,7,8,9,10-hexahydro-9-methyl-8-oxopyrazolo[3,4-i][2]benzazepin-7-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 885606-83-7 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[(7R)-3,6,7,8,9,10-hexahydro-8-oxo-9-[2-(1-piperidinyl)ethyl]pyrazolo[3,4-i][2]benzazepin-7-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 885606-84-8 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[(7R)-3,6,7,8,9,10-hexahydro-8-oxo-9-[2-(1-pyrrolidinyl)ethyl]pyrazolo[3,4-i][2]benzazepin-7-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 885606-86-0 CAPLUS


CN 1-Piperidinecarboxamide, 4-((1R)-4-(2-(dimethylamino)ethyl)-1,4-dihydro-2-oxo-3H-quinazolin-1-yl)-N-((7R)-9-[2-(dimethylamino)ethyl]-3,6,7,8,9,10-hexahydro-8-oxopyrazolo[3,4-i][2]benzazepin-7-yl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 885606-88-2 CAPLUS


CN 6H-Pyrazolo[3,4-g]quinolin-6-one, 7-([2-[[4-(1,4-dihydro-2-oxo-3H-quinazolin-1-yl)-1-piperidinyl]-2-oxoethyl]-5-(2,2-dimethylpropyl)-1,5,7,8-tetrahydro- (CA INDEX NAME)



RN 885606-90-6 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[(7R)-3,6,7,8,9,10-hexahydro-9-[2-(4-morpholinyl)ethyl]-8-oxopyrazolo[3,4-i][2]benzazepin-7-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 885606-94-0 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[(7R)-3,6,7,8,9,10-hexahydro-8-oxo-9-[(1S)-1-phenylethyl]pyrazolo[3,4-i][2]benzazepin-7-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 885606-95-1 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[(7R)-3,6,7,8,9,10-hexahydro-8-oxo-9-[(1R)-1-phenylethyl]pyrazolo[3,4-i][2]benzazepin-7-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 885606-96-2 CAPLUS

CN 1-Piperidinecarboxamide, N-[(7R)-4-chloro-3,6,7,8,9,10-hexahydro-8-oxo-9-(phenylmethyl)pyrazolo[3,4-i][2]benzazepin-7-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885606-97-3 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[(7R)-3,6,7,8,9,10-hexahydro-8-oxo-9-[[4-(trifluoromethyl)phenyl]methyl]pyrazolo[3,4-i][2]benzazepin-7-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 885606-99-5 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[(7R)-3,6,7,8,9,10-hexahydro-9-(1-methylethyl)-8-oxopyrazolo[3,4-i][2]benzazepin-7-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-00-1 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[(7R)-9-(3,3-dimethylbutyl)-3,6,7,8,9,10-hexahydro-8-oxopyrazolo[3,4-i][2]benzazepin-7-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-01-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(7R)-7-[[[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]carbonyl]amino]-6,7,8,10-tetrahydro-8-oxopyrazolo[3,4-i][2]benzazepin-9(3H)-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-02-3 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[(7R)-3,6,7,8,9,10-hexahydro-8-oxo-9-(4-piperidinyl)pyrazolo[3,4-i][2]benzazepin-7-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-03-4 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 7-[2-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-oxoethyl]-9-(2,2-dimethylpropyl)-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-04-5 CAPLUS

CN 1-Piperidinecarboxamide, N-[(7R)-4-chloro-9-(2,2-dimethylpropyl)-3,6,7,8,9,10-hexahydro-8-oxopyrazolo[3,4-i][2]benzazepin-7-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-05-6 CAPLUS


CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-oxoethyl]-9-(2,2-dimethylpropyl)-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 885607-06-7 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[9-(2,2-dimethylpropyl)-3,6,7,8,9,10-hexahydro-8-oxopyrazolo[3,4-i][2]benzazepin-7-yl]- (CA INDEX NAME)




RN 885607-08-9 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[3,6,7,8,9,10-hexahydro-9-(2-methylpropyl)-8-oxopyrazolo[3,4-i][2]benzazepin-7-yl]- (CA INDEX NAME)




RN 885607-10-3 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[3,6,7,8,9,10-hexahydro-8-oxo-9-[2-(4-pyridinyl)ethyl]pyrazolo[3,4-i][2]benzazepin-7-yl]- (CA INDEX NAME)






RN 885607-12-5 CAPLUS


CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[3,6,7,8,9,10-hexahydro-8-oxo-9-(4-pyridinylmethyl)pyrazolo[3,4-i][2]benzazepin-7-yl]- (CA INDEX NAME)



RN 885607-14-7 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-(3,6,7,8,9,10-hexahydro-4,9-dimethyl-8-oxopyrazolo[3,4-i][2]benzazepin-7-yl)- (CA INDEX NAME)






RN 885607-20-5 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 7-[2-[4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)-1-piperidinyl]-2-oxoethyl]-9-(2,2-dimethylpropyl)-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-21-6 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[(6R)-1,5,6,7,8,9-hexahydro-7-oxo-8-(phenylmethyl)pyrazolo[4,3-h][2]benzazepin-6-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-22-7 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 7-[2-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(phenylmethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-23-8 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 9-(2,2-dimethylpropyl)-7-[2-[4-(8-fluoro-1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-24-9 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-9-(2,2-dimethylpropyl)-7-[2-[4-(8-fluoro-1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-26-1 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 7-[2-[4-(1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-9-(2,2-dimethylpropyl)-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-27-2 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-9-(2,2-dimethylpropyl)-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-28-3 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)-1-piperidinyl]-2-oxoethyl]-9-(2,2-dimethylpropyl)-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-29-4 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-[2,3-dihydro-2-oxo-4-(2-pyridinyl)-1H-imidazol-1-yl]-1-piperidinyl]-2-oxoethyl]-9-(2,2-dimethylpropyl)-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-31-8 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-9-(2,2-dimethylpropyl)-7-[2-[4-(8-fluoro-1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-32-9 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(3,4-dihydro-3-oxo-2-quinoxaliny)-1-piperidinyl]-2-oxoethyl]-9-(2,2-dimethylpropyl)-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-33-0 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(4-pyridinylmethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-34-1 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(8-fluoro-1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(4-pyridinylmethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-35-2 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(8-fluoro-1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(4-pyridinylmethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-36-3 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(4-pyridinylmethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-37-4 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(4-pyridinylmethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-38-5 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolin-2-yl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(1H-imidazol-2-ylmethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-39-6 CAPLUS

CN 1-Piperidinecarboxamide, N-[(4R)-8-amino-2,3,4,5-tetrahydro-7-methyl-3-oxo-2-(phenylmethyl)-1H-2-benzazepin-4-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-40-9 CAPLUS


CN 1-Piperidinecarboxamide, N-[(4R)-8-amino-2,3,4,5-tetrahydro-9-methyl-3-oxo-2-(phenylmethyl)-1H-2-benzazepin-4-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 885607-41-0 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(7R)-3,6,7,8,9,10-hexahydro-8-oxo-9-(phenylmethyl)pyrazolo[3,4-i][2]benzazepin-7-yl]-4-(1,2,3,4-tetrahydro-2-oxo-3-quinolinyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 885607-46-5 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(7R)-9-(1-acetyl-4-piperidinyl)-3,6,7,8,9,10-hexahydro-8-oxopyrazolo[3,4-i][2]benzazepin-7-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 885607-47-6 CAPLUS
 CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[(7R)-3,6,7,8,9,10-hexahydro-8-oxo-9-(3-pyrrolidinyl)pyrazolo[3,4-i][2]benzazepin-7-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-48-7 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 7-[2-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]ethyl]-9-(2,2-dimethylpropyl)-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-50-1 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 7-[2-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-oxoethyl]-9-(2,2-dimethylpropyl)-6,7,9,10-tetrahydro-, (7R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-51-2 CAPLUS

CN 1-Piperidinecarboxamide, N-[(7R)-9-(2,2-dimethylpropyl)-3,6,7,8,9,10-hexahydro-8-oxopyrazolo[3,4-i][2]benzazepin-7-yl]-4-(1,2,3,4-tetrahydro-2-oxo-3-quinolinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-59-0 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-61-4 CAPLUS

CN 2,4-Imidazolidinedione, 3-[1-[2-[(7S)-4-chloro-9-(2,2-dimethylpropyl)-3,6,7,8,9,10-hexahydro-8-oxopyrazolo[3,4-i][2]benzazepin-7-yl]acetyl]-4-piperidinyl]-1-phenyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-62-5 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(1,4-dihydro-2-oxopyrido[2,3-d]pyrimidin-3(2H)-yl)-1-piperidinyl]-2-oxoethyl]-9-(2,2-dimethylpropyl)-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-63-6 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(1,2-dihydro-2-oxo-1,8-naphthyridin-3-yl)-1-piperidinyl]-2-oxoethyl]-9-(2,2-dimethylpropyl)-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-64-7 CAPLUS


CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(1,2-dihydro-2-oxo-1,6-naphthyridin-3-yl)-1-piperidinyl]-2-oxoethyl]-9-(2,2-dimethylpropyl)-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 885607-72-7 CAPLUS


CN 1-Piperidinecarboximidamide, N-cyano-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N'-[9-(2,2-dimethylpropyl)-3,6,7,8,9,10-hexahydro-8-oxopyrazolo[3,4-i][2]benzazepin-7-yl]- (CA INDEX NAME)



RN 885607-73-8 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(1,2-dihydro-2-oxo-1,8-naphthyridin-3-yl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-74-9 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-75-0 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(8-fluoro-1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-78-3 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-bromo-7-[2-[4-(1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-9-(2,2-dimethylpropyl)-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-79-4 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-bromo-9-(2,2-dimethylpropyl)-7-[2-[4-(8-fluoro-1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-80-7 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-bromo-7-[2-[4-(1,2-dihydro-2-oxo-1,8-naphthyridin-3-yl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-81-8 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-bromo-7-[2-[4-(1,2-dihydro-2-oxo-3-quinoliny)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-82-9 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-bromo-7-[2-[4-(8-fluoro-1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-83-0 CAPLUS

CN 1-Piperidinecarboximidamide, N-[(7R)-4-chloro-9-(2,2-dimethylpropyl)-3,6,7,8,9,10-hexahydro-8-oxopyrazolo[3,4-i][2]benzazepin-7-yl]-N'-cyano-4-(1,2-dihydro-2-oxo-3-quinolinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-84-1 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 7-[2-[4-(1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-9-(2,2-dimethylpropyl)-6,7,9,10-tetrahydro-4-methyl-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-85-2 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 9-(2,2-dimethylpropyl)-7-[2-[4-(8-fluoro-1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-4-methyl-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-86-3 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 7-[2-[4-(1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-4-methyl-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-87-4 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 7-[2-[4-(8-fluoro-1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-4-methyl-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-88-5 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 7-[2-[4-(1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-9-(2,2-dimethylpropyl)-6,7,9,10-tetrahydro-4-(1-methylethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-89-6 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 9-(2,2-dimethylpropyl)-7-[2-[4-(8-fluoro-1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-4-(1-methylethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-90-9 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 7-[2-[4-(1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-4-(1-methylethyl)-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-91-0 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 7-[2-[4-(8-fluoro-1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-4-(1-methylethyl)-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-92-1 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 7-[2-[4-(1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-4-(1-methylethenyl)-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-93-2 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 7-[2-[4-(8-fluoro-1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-4-(1-methylethenyl)-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-94-3 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-ethyl-7-[2-[4-(8-fluoro-1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(2,2,2-trifluoroethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-95-4 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-bromo-9-(cyclopropylmethyl)-7-[2-[4-(1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-96-5 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-bromo-9-(cyclopropylmethyl)-7-[2-[4-(8-fluoro-1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-97-6 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-bromo-7-[2-[4-(1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(2-methoxyethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-98-7 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-bromo-7-[2-[4-(8-fluoro-1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-9-(2-methoxyethyl)-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885607-99-8 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(6,7-difluoro-1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-9-(2,2-dimethylpropyl)-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885608-00-4 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(7-chloro-1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-9-(2,2-dimethylpropyl)-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885608-01-5 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-7-[2-[4-(8-chloro-1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-9-(2,2-dimethylpropyl)-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885608-02-6 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-9-(2,2-dimethylpropyl)-7-[2-[4-(5-fluoro-1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885608-03-7 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-9-(2,2-dimethylpropyl)-7-[2-[4-(7-fluoro-1,2-dihydro-2-oxo-1,8-naphthyridin-3-yl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885608-04-8 CAPLUS

CN Pyrazolo[3,4-i][2]benzazepin-8(3H)-one, 4-chloro-9-(2,2-dimethylpropyl)-7-[2-[4-(7-fluoro-1,2-dihydro-2-oxo-3-quinolinyl)-1-piperidinyl]-2-oxoethyl]-6,7,9,10-tetrahydro-, (7S)- (CA INDEX NAME)

Absolute stereochemistry.



IT 885608-26-4P 885608-96-8P 885609-01-8P

885609-11-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of constrained indazoloazepinones and related compds. as CGRP-receptor antagonists and useful for treatment of migraine)

RN 885608-26-4 CAPLUS

CN 1-Piperidinecarboxamide, N-[(7R)-3-acetyl-3,6,7,8,9,10-hexahydro-8-oxo-9-(phenylmethyl)pyrazolo[3,4-i][2]benzazepin-7-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885608-96-8 CAPLUS

CN Carbamic acid, N-[(4R)-4-[[[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]carbonyl]amino]-2,3,4,5-tetrahydro-7-methyl-3-oxo-2-(phenylmethyl)-1H-2-benzazepin-8-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 885609-01-8 CAPLUS

CN Carbamic acid, N-[(4R)-4-[[[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]carbonyl]amino]-2,3,4,5-tetrahydro-9-methyl-3-oxo-2-(phenylmethyl)-1H-2-benzazepin-8-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 885609-11-0 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 3-[(7R)-7-[[[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]carbonyl]amino]-6,7,8,10-tetrahydro-8-oxopyrazolo[3,4-i][2]benzazepin-9(3H)-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 14 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2005:732540 CAPLUS Full-text
 DN 143:211942
 TI Preparation of diazepanones and related derivatives as CGRP receptor antagonists
 IN Burgey, Christopher S.; Paone, Daniel V.; Shaw, Anthony W.; Stump, Craig A.; Williams, Theresa M.
 PA Merck & Co., Inc., USA
 SO PCT Int. Appl., 143 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005072308	A2	20050811	WO 2005-US2199	20050125
	WO 2005072308	A9	20060202		
	WO 2005072308	A3	20070322		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2005208834	A1	20050811	AU 2005-208834	20050125
	CA 2554351	A1	20050811	CA 2005-2554351	20050125
	EP 1765805	A2	20070328	EP 2005-711919	20050125
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU			
	JP 2007519729	T	20070719	JP 2006-551371	20050125
	IN 2006DN04344	A	20070824	IN 2006-DN4344	20060727
	CN 101124217	A	20080213	CN 2005-80003493	20060728
	US 2007287696	A1	20071213	US 2007-587121	20070514
PRAI	US 2004-539957P	P	20040129		
	WO 2005-US2199	W	20050125		
OS	MARPAT 143:211942				
GI					

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I and II [wherein A = a bond, C(R2)2, S, SO, SO2, NR2; B = [C(R2)2]p; D = O; R1 = H, (un)substituted cyclo/alkyl, hetero/aryl, etc.; R2 = H, (un)substituted alk(en/yn)yl, hetero/aryl, SO2NH2 and derivs., etc.; R2CR2 = (un)substituted cyclobutyl, cyclopent(en)yl, pyrrolidinyl, oxazolinyl, etc.; W = O, NH and derivs., CH2 and derivs.; X = C, S; Y = O, NCN, NCONH2, etc.; or Y = O2 when X = S; G-J = N, C, N-CH2 and derivs., C:N, etc.; Q-T = CH:CH and derivs., CH2-CH2 and derivs., N:N, N, N:CH and derivs., etc.; each R3 = independently H, CN, CO2H and derivs., (un)substituted alkyl; n = 1-9; and their pharmaceutically acceptable salts and individual diastereomers] were prepared as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache,

migraine and cluster headache. For example, reacting 4-(2-oxo-4-phenyl-2,3-dihydro-1H-imidazol-1-yl)piperidinium chloride with COCl₂, and (3R,7R)-3-amino-1-(cyclopropylmethyl)-7-phenylazepan-2-one gave azepanone II. I displayed antagonistic activity in both a binding and a functional assay with K_i or IC₅₀ values of less than about 50 μM.


IT 862280-74-8P, N-[trans-1-(Cyclopropylmethyl)-7-oxo-3-phenyl-1,4-diazepan-6-yl]-4-(2-oxo-4-phenyl-2,3-dihydro-1H-imidazol-1-yl)piperidine-1-carboxamide

RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of diazepanones and related derivs. as CGRP receptor antagonists)

RN 862280-74-8 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-1-(cyclopropylmethyl)hexahydro-7-oxo-3-phenyl-1H-1,4-diazepin-6-yl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)-, rel- (CA INDEX NAME)

Relative stereochemistry.




IT 862280-73-7P, N-[(3R,6S)-1-(Cyclopropylmethyl)-7-oxo-3-phenyl-1,4-diazepan-6-yl]-4-(2-oxo-4-phenyl-2,3-dihydro-1H-imidazol-1-yl)piperidine-1-carboxamide

RL: PAC (Pharmacological activity); PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of diazepanones and related derivs. as CGRP receptor antagonists)

RN 862280-73-7 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-1-(cyclopropylmethyl)hexahydro-7-oxo-3-phenyl-1H-1,4-diazepin-6-yl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.



IT 862280-72-6P, N-[(3S,6R)-1-(Cyclopropylmethyl)-7-oxo-3-phenyl-1,4-diazepan-6-yl]-4-(2-oxo-4-phenyl-2,3-dihydro-1H-imidazol-1-yl)piperidine-1-

carboxamide


RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of diazepanones and related derivs. as CGRP receptor antagonists)

RN 862280-72-6 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3S,6R)-1-(cyclopropylmethyl)hexahydro-7-oxo-3-phenyl-1H-1,4-diazepin-6-yl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.



IT 862280-70-4P, tert-Butyl trans-4-(cyclopropylmethyl)-5-oxo-6-[[[4-(2-oxo-4-phenyl-2,3-dihydro-1H-imidazol-1-yl)piperidin-1-yl]carbonyl]amino]-2-phenyl-1,4-diazepane-1-carboxylate


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate; preparation of diazepanones and related derivs. as CGRP receptor antagonists)

RN 862280-70-4 CAPLUS

CN 1H-1,4-Diazepine-1-carboxylic acid, 4-(cyclopropylmethyl)-6-[[[4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)-1-piperidinyl]carbonyl]amino]hexahydro-5-oxo-2-phenyl-, 1,1-dimethylethyl ester, (2S,6R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 862280-67-9P, N-[(3S,6R)-1-(Cyclopropylmethyl)-2-oxo-6-phenylazepan-3-yl]-4-(2-oxo-4-phenyl-2,3-dihydro-1H-imidazol-1-yl)piperidine-1-carboxamide 862280-75-9P, N-[cis-1-(Cyclopropylmethyl)-7-oxo-3-phenyl-1,4-diazepan-6-yl]-4-(2-oxo-4-phenyl-2,3-dihydro-1H-imidazol-1-yl)piperidine-1-carboxamide 862280-77-1P, N-[(2S,6R)-4-(Cyclopropylmethyl)-1-methyl-5-oxo-2-phenyl-1,4-diazepan-6-yl]-4-(2-oxo-4-phenyl-2,3-dihydro-1H-imidazol-1-yl)piperidine-1-

carboxamide 862280-78-2P, N-[(2S,6R)-1-Benzyl-4-(cyclopropylmethyl)-5-oxo-2-phenyl-1,4-diazepan-6-yl]-4-(2-oxo-4-phenyl-2,3-dihydro-1H-imidazol-1-yl)piperidine-1-carboxamide 862280-79-3P, N-[(2S,6R)-1-Acetyl-4-(cyclopropylmethyl)-5-oxo-2-phenyl-1,4-diazepan-6-yl]-4-(2-oxo-4-phenyl-2,3-dihydro-1H-imidazol-1-yl)piperidine-1-carboxamide 862280-80-6P, N-[(3R,7R)-1-(Cyclopropylmethyl)-2-oxo-7-phenylazepan-3-yl]-4-(2-oxo-4-phenyl-2,3-dihydro-1H-imidazol-1-yl)piperidine-1-carboxamide 862280-81-7P, N-[(3R,6S)-1-(Cyclopropylmethyl)-2-oxo-6-phenylazepan-3-yl]-4-(5-oxo-3-phenyl-4,5-dihydro-1H-1,2,4-triazol-1-yl)piperidine-1-carboxamide 862280-82-8P, N-[(3R,6S)-6-(2,3-Difluorophenyl)-1-(2-methoxyethyl)-2-oxoazepan-3-yl]-4-(2-oxo-4-phenylimidazolidin-1-yl)piperidine-1-carboxamide 862280-83-9P, N-[(3R,6S)-6-(2,3-Difluorophenyl)-1-(2-methoxyethyl)-2-oxoazepan-3-yl]-4-(2,4-dioxoimidazolidin-1-yl)piperidine-1-carboxamide 862280-84-0P, N-[(3R,6S)-6-(2,3-Difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(3-oxo-2,3-dihydropyridazin-4-yl)piperidine-1-carboxamide 862280-87-3P 862280-88-4P

862280-89-5P 862280-90-8P 862280-91-9P

862280-92-0P 862280-93-1P 862280-96-4P

862280-97-5P 862280-98-6P 862280-99-7P

862281-00-3P 862281-01-4P 862281-02-5P

862281-03-6P 862281-04-7P 862281-05-8P

862281-06-9P 862281-07-0P 862281-08-1P

862281-09-2P 862281-12-7P 862281-13-8P

862281-14-9P 862281-15-0P 862281-16-1P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of diazepamones and related derivs. as CGRP receptor antagonists)

RN 862280-67-9 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3S,6R)-1-(cyclopropylmethyl)hexahydro-2-oxo-6-phenyl-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)-(CA INDEX NAME)


Absolute stereochemistry.



RN 862280-75-9 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6R)-1-(cyclopropylmethyl)hexahydro-7-oxo-3-phenyl-1H-1,4-diazepin-6-yl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 862280-77-1 CAPLUS

CN 1-Piperidinecarboxamide, N-[(2S,6R)-4-(cyclopropylmethyl)hexahydro-1-methyl-5-oxo-2-phenyl-1H-1,4-diazepin-6-yl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 862280-78-2 CAPLUS

CN 1-Piperidinecarboxamide, N-[(2S,6R)-4-(cyclopropylmethyl)hexahydro-5-oxo-2-phenyl-1-(phenylmethyl)-1H-1,4-diazepin-6-yl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 862280-79-3 CAPLUS

CN 1-Piperidinecarboxamide, N-[(2S,6R)-1-acetyl-4-(cyclopropylmethyl)hexahydro-5-oxo-2-phenyl-1H-1,4-diazepin-6-yl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 862280-80-6 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R, 7R)-1-(cyclopropylmethyl)hexahydro-2-oxo-7-phenyl-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 862280-81-7 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R, 6S)-1-(cyclopropylmethyl)hexahydro-2-oxo-6-phenyl-1H-azepin-3-yl]-4-(2,5-dihydro-5-oxo-3-phenyl-1H-1,2,4-triazol-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 862280-82-8 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R, 6S)-6-(2,3-difluorophenyl)hexahydro-1-(2-

methoxyethyl)-2-oxo-1H-azepin-3-yl]-4-(2-oxo-4-phenyl-1-imidazolidinyl)-
(CA INDEX NAME)


Absolute stereochemistry.



RN 862280-83-9 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-1-(2-methoxyethyl)-2-oxo-1H-azepin-3-yl]-4-(2,4-dioxo-1-imidazolidinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 862280-84-0 CAPLUS


CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-2-oxo-1-(2,2,2-trifluoroethyl)-1H-azepin-3-yl]-4-(2,3-dihydro-3-oxo-4-pyridazinyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 862280-87-3 CAPLUS


CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)-N-[hexahydro-2-oxo-1-(phenylmethyl)-1H-azepin-3-yl]- (CA INDEX NAME)



RN 862280-88-4 CAPLUS

CN 1H-Azepine-1-acetic acid, 3-[[[4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)-1-piperidinyl]carbonyl]amino]hexahydro-2-oxo-7-phenyl-, 1,1-dimethylethyl ester, (3S,7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 862280-89-5 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3S,7S)-1-(cyclopropylmethyl)hexahydro-2-oxo-7-phenyl-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 862280-90-8 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-1-(cyclopropylmethyl)hexahydro-2-oxo-6-phenyl-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)-
(CA INDEX NAME)


Absolute stereochemistry.



RN 862280-91-9 CAPLUS

CN 1-Piperidinecarboxamide, N-[(2S,6S)-4-(cyclopropylmethyl)hexahydro-5-oxo-2-phenyl-1,4-thiazepin-6-yl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)-
(CA INDEX NAME)


Absolute stereochemistry.



RN 862280-92-0 CAPLUS


CN 1-Piperidinecarboxamide, N-[(2S,6S)-4-(cyclopropylmethyl)hexahydro-1,1-dioxido-5-oxo-2-phenyl-1,4-thiazepin-6-yl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 862280-93-1 CAPLUS


CN 1-Piperidinecarboxamide, N-[1-(cyclopropylmethyl)-2-oxo-5-phenyl-3-piperidinyl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)- (CA INDEX NAME)



RN 862280-96-4 CAPLUS

CN 1-Piperidinecarboxamide, N-[(2R,6R)-4-(cyclopropylmethyl)hexahydro-5-oxo-2-phenyl-1,4-oxazepin-6-yl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 862280-97-5 CAPLUS

CN 1-Piperidinecarboxamide, N-[(2R,6S)-4-(cyclopropylmethyl)hexahydro-5-oxo-2-phenyl-1,4-oxazepin-6-yl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 862280-98-6 CAPLUS

CN 1-Piperidinecarboxamide, N-[(2S,6R)-4-(cyclopropylmethyl)hexahydro-5-oxo-2-phenyl-1,4-oxazepin-6-yl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 862280-99-7 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,5R)-1-(cyclopropylmethyl)hexahydro-2-oxo-5-phenyl-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 862281-00-3 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,5S)-1-(cyclopropylmethyl)hexahydro-2-oxo-5-phenyl-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 862281-01-4 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-1-[2-(methylthio)ethyl]-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 862281-02-5 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-1-(2-hydroxyethyl)-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 862281-03-6 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-2-oxo-1-[2-(trifluoromethoxy)ethyl]-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 862281-04-7 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-1-(2-methoxyethyl)-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 862281-05-8 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)-N-[(3R)-hexahydro-2-oxo-1-(phenylmethyl)-1H-azepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 862281-06-9 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)-N-[(3R)-hexahydro-2-oxo-1-[[4-(phenylmethoxy)phenyl]methyl]-1H-azepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 862281-07-0 CAPLUS

CN 1-Piperidinecarboxamide, N-[(2S,6R)-4-(cyclopropylmethyl)hexahydro-5-oxo-2-phenyl-1,4-oxazepin-6-yl]-4-(2,5-dihydro-5-oxo-3-phenyl-1H-1,2,4-triazol-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 862281-08-1 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,5R)-1-(cyclopropylmethyl)hexahydro-2-oxo-5-phenyl-1H-azepin-3-yl]-4-(2,5-dihydro-5-oxo-3-phenyl-1H-1,2,4-triazol-1-yl)-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 862281-09-2 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,5S)-1-(cyclopropylmethyl)hexahydro-2-oxo-5-phenyl-1H-azepin-3-yl]-4-(2,5-dihydro-5-oxo-3-phenyl-1H-1,2,4-triazol-1-yl)-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 862281-12-7 CAPLUS

CN 1-Piperidinecarboxamide, N-[(2S,6S)-4-(cyclopropylmethyl)hexahydro-5-oxo-2-phenyl-1,4-oxazepin-6-yl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)-
(CA INDEX NAME)


Absolute stereochemistry.



RN 862281-13-8 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,5R)-1-(cyclopropylmethyl)hexahydro-2-oxo-5-phenyl-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)-
(CA INDEX NAME)

Absolute stereochemistry.




RN 862281-14-9 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,5S)-1-(cyclopropylmethyl)hexahydro-2-oxo-5-

phenyl-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)-
(CA INDEX NAME)


Absolute stereochemistry.



RN 862281-15-0 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,5R)-1-(cyclopropylmethyl)hexahydro-2-oxo-5-phenyl-1H-azepin-3-yl]-4-(2,5-dihydro-5-oxo-3-phenyl-1H-1,2,4-triazol-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 862281-16-1 CAPLUS


CN 1-Piperidinecarboxamide, N-[(3R,5S)-1-(cyclopropylmethyl)hexahydro-2-oxo-5-phenyl-1H-azepin-3-yl]-4-(2,5-dihydro-5-oxo-3-phenyl-1H-1,2,4-triazol-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.




IT 862280-76-0P, tert-Butyl cis-4-(cyclopropylmethyl)-5-oxo-6-[[[4-(2-oxo-4-phenyl-2,3-dihydro-1H-imidazol-1-yl)piperidin-1-yl]carbonyl]amino]-2-phenyl-1,4-diazepane-1-carboxylate
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of diazepanones and related derivs. as CGRP receptor antagonists)
 RN 862280-76-0 CAPLUS
 CN 1H-1,4-Diazepine-1-carboxylic acid, 4-(cyclopropylmethyl)-6-[[[4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)-1-piperidinyl]carbonyl]amino]hexahydro-5-oxo-2-phenyl-, 1,1-dimethylethyl ester, (2R,6R)-rel- (CA INDEX NAME)

Relative stereochemistry.



L5 ANSWER 15 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2005:419750 CAPLUS Full-text
 DN 143:133341
 TI Stereoselective Synthesis of New Conformationally Restricted Analogues of
 a Potent CGRP Receptor Antagonist
 AU Zuev, Dmitry; Michne, Jodi A.; Huang, Hong; Beno, Brett R.; Wu, Dedong;
 Gao, Qi; Torrente, John R.; Xu, Cen; Conway, Charles M.; Macor, John E.;
 Dubowchik, Gene M.
 CS Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, CT,
 06492, USA
 SO Organic Letters (2005), 7(12), 2465-2468
 CODEN: ORLEF7; ISSN: 1523-7060
 PB American Chemical Society
 DT Journal
 LA English
 OS CASREACT 143:133341
 AB A stereocontrolled racemic synthesis of conformationally restricted analogs of
 a potent CGRP receptor antagonist [i.e., N-[(1R)-1-[(3,5- dibromo-4-
 hydroxyphenyl)methyl]-2-oxo-2-(4-phenyl-1-piperazinyl)ethyl]-4- (2,3-dihydro-
 2-oxo-1H-benzimidazol-1-yl)-1-piperidinecarboxamide] by novel
 functionalization of 2-substituted pyrido[1,2-a]pyrazin-6-ones is described.
 The new diastereoselective LDA-promoted α -nitration of intermediate lactams
 established the required trans-configuration in the desired products.
 IT 858681-77-3P 858681-79-5P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL
 (Biological study); PREP (Preparation)
 (stereoselective synthesis of conformationally restricted analogs of
 N-[(R)-[(dibromo hydroxyphenyl)methyl] oxo (Ph piperazinyl)ethyl] (oxo
 benzimidazolyl) piperidinecarboxamide (CGRP receptor antagonist))
 RN 858681-77-3 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(7R,9aR)-7-[(3,5-dibromo-4-
 hydroxyphenyl)methyl]octahydro-6-oxo-2-phenyl-2H-pyrido[1,2-a]pyrazin-7-
 yl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, rel-,
 mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)
 CM 1
 CRN 858681-76-2
 CMF C34 H36 Br2 N6 O4


Relative stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 858681-79-5 CAPLUS


CN 1-Piperidinecarboxamide, N-[(7R,9aR)-7-[(3,5-dibromo-4-hydroxyphenyl)methyl]octahydro-6-oxo-2-(phenylmethyl)-2H-pyrido[1,2-a]pyrazin-7-yl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, rel-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 858681-78-4

CMF C35 H38 Br2 N6 O4


Relative stereochemistry.



CM 2


CRN 76-05-1

CMF C2 H F3 O2




IT 858681-73-9P 858681-75-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (stereoselective synthesis of conformationally restricted analogs of
 N-[(R)-[(dibromo hydroxyphenyl)methyl] oxo (Ph piperazinyl)ethyl] (oxo
 benzimidazolyl) piperidinecarboxamide (CGRP receptor antagonist))
 RN 858681-73-9 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(7R,9aR)-7-[(3,5-dibromo-4-
 methoxyphenyl)methyl]octahydro-6-oxo-2-phenyl-2H-pyrido[1,2-a]pyrazin-7-
 yl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, rel-,
 mono(trifluoroacetate) (9CI) (CA INDEX NAME)
 CM 1
 CRN 858681-72-8
 CMF C35 H38 Br2 N6 O4

Relative stereochemistry.



CM 2
 CRN 76-05-1
 CMF C2 H F3 O2




RN 858681-75-1 CAPLUS
CN 1-Piperidinecarboxamide, N-[(7R,9aR)-7-[(3,5-dibromo-4-methoxyphenyl)methyl]octahydro-6-oxo-2-(phenylmethyl)-2H-pyrido[1,2-a]pyrazin-7-yl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, rel-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 858681-74-0
CMF C36 H40 Br2 N6 O4

Relative stereochemistry.



CM 2



CRN 76-05-1
CMF C2 H F3 O2



RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 16 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2004:902378 CAPLUS Full-text
 DN 141:379817
 TI Preparation of piperidine derivatives as CGRP receptor antagonists
 IN Burgey, Christopher S.; Deng, Zhengwu J.; Nguyen, Diem N.; Paone, Daniel
 V.; Shaw, Anthony W.; Williams, Theresa M.
 PA Merck & Co., Inc., USA
 SO PCT Int. Appl., 71 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004092168	A1	20041028	WO 2004-US11280	20040409
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	BR 2004009601	A	20060418	BR 2004-9601	20040409
	CN 1802376	A	20060712	CN 2004-80016115	20040409
	RU 2308458	C2	20071020	RU 2005-135440	20040409
	IN 2005DN04609	A	20070817	IN 2005-DN4609	20051010
	MX 2005PA11166	A	20051214	MX 2005-PA11166	20051014
	KR 769030	B1	20071022	KR 2005-719692	20051014
	NO 2005005375	A	20051114	NO 2005-5375	20051114
PRAI	US 2003-463089P	P	20030415		
	US 2003-510352P	P	20031010		
	WO 2004-US11280	W	20040409		
OS	MARPAT 141:379817				
GI					



AB Title compds. I [R1 = H, (un)substituted-alkyl, -cycloalkyl, etc.; R2 = H, (un)substituted-alkyl, -heterocyclyl, -aryl, etc.; R3 = H, CN, CO₂H, (un)substituted alkyl or ester], and their pharmaceutically acceptable salts, are prepared and disclosed as antagonists of CGRP receptors. Thus, e.g., II was prepared by acylation of (3R,6S)-3-amino-1-(2-methoxyethyl)-6-phenylazepan-2-one (preparation given) with 4-nitrophenylchloroformate and subsequent amidation with 2-oxo-1-piperidinium-4-yl-2,3-dihydro-1H-imidazo[4,5-b]pyridin-4-ium dichloride. I are useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. I possessed K_i or IC₅₀ values of less than about 50 μM in CGRP receptor antagonist assays. The invention is also directed to pharmaceutical compns. comprising these compds. and the use of these compds. and compns. in the prevention or treatment of such diseases in which CGRP is involved.

IT 781648-80-4P 781648-81-5P 781648-82-6P
 781648-83-7P 781648-84-8P 781648-85-9P
 781648-86-0P 781648-87-1P 781648-88-2P
 781648-89-3P 781648-90-6P 781648-91-7P
 781648-92-8P 781648-93-9P 781648-94-0P
 781648-95-1P 781648-96-2P 781648-97-3P
 781648-98-4P 781649-00-1P 781649-01-2P
 781649-02-3P 781649-03-4P 781649-04-5P
 781649-05-6P 781649-06-7P 781649-07-8P
 781649-08-9P 781649-09-0P 781649-10-3P
 781649-11-4P 781649-12-5P 781649-13-6P
 781649-14-7P 781649-15-8P 781649-16-9P
 781649-17-0P 781649-18-1P 781649-19-2P
 781649-20-5P 781649-21-6P 781649-22-7P
 781649-23-8P 781649-24-9P 781649-25-0P
 781649-26-1P 781649-27-2P 781649-28-3P
 781649-29-4P 781649-30-7P 781649-31-8P
 781649-32-9P 781649-33-0P 781649-34-1P
 781649-35-2P 781649-36-3P 781649-37-4P
 781649-38-5P 781649-39-6P 781649-40-9P
 781649-41-0P 781649-42-1P 781649-43-2P
 781649-44-3P 781649-45-4P 781649-46-5P

781649-47-6P 781649-48-7P 781649-49-8P
 781649-50-1P 781649-51-2P 781649-52-3P
 781649-53-4P 781649-54-5P 781649-55-6P
 781649-56-7P 781649-57-8P 781649-58-9P
 781649-59-0P 781649-60-3P 781649-61-4P
 781649-63-6P 781649-64-7P 781649-66-9P
 781649-68-1P 781649-69-2P 781649-70-5P
 781649-72-7P 781649-74-9P 781649-76-1P
 781649-78-3P 781649-80-7P 781649-82-9P
 781650-61-1P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of heterocyclic piperidine derivs. as CGRP receptor antagonists)

RN 781648-80-4 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-[(3R,6S)-hexahydro-1-(2-methoxyethyl)-2-oxo-6-phenyl-1H-azepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 781648-81-5 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-[(3R,6S)-hexahydro-2-oxo-6-phenyl-1H-azepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 781648-82-6 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-[(3R,6R)-hexahydro-2-oxo-6-phenyl-1H-azepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 781648-83-7 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-[(3R,6S)-hexahydro-1-methyl-2-oxo-6-phenyl-1H-azepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 781648-84-8 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-[(3R,6S)-1-ethylhexahydro-2-oxo-6-phenyl-1H-azepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 781648-85-9 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-[(3R,6S)-hexahydro-2-oxo-6-phenyl-1-(2,2,2-trifluoroethyl)-1H-azepin-3-yl]- (CA INDEX NAME)

3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 781648-86-0 CAPLUS

CN 1H-Azepine-1-acetic acid, 3-[[[4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-1-piperidinyl]carbonyl]amino]hexahydro-2-oxo-6-phenyl-, methyl ester, (3R,6S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 781648-87-1 CAPLUS

CN 1H-Azepine-1-acetic acid, 3-[[[4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-1-piperidinyl]carbonyl]amino]hexahydro-2-oxo-6-phenyl-, (3R,6S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 781648-88-2 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-[(3R,6S)-1-(2-ethoxyethyl)hexahydro-2-oxo-6-phenyl-1H-azepin-3-yl]-
(CA INDEX NAME)


Absolute stereochemistry.



RN 781648-89-3 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-1-(cyanomethyl)hexahydro-2-oxo-6-phenyl-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-
(CA INDEX NAME)


Absolute stereochemistry.



RN 781648-90-6 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-[(3R,6S)-hexahydro-1-(2-hydroxyethyl)-2-oxo-6-phenyl-1H-azepin-3-yl]-
(CA INDEX NAME)


Absolute stereochemistry.



RN 781648-91-7 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-1-(cyclopropylmethyl)hexahydro-2-oxo-6-phenyl-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 781648-92-8 CAPLUS


CN 1H-Azepine-1-acetamide, 3-[[[4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-1-piperidinyl]carbonyl]amino]hexahydro-N,N-dimethyl-2-oxo-6-phenyl-, (3R,6S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 781648-93-9 CAPLUS
CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-[(3R)-hexahydro-6-(4-hydroxyphenyl)-2-oxo-1H-azepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 781648-94-0 CAPLUS
CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-[(3R)-6-(2-fluorophenyl)hexahydro-2-oxo-1H-azepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 781648-95-1 CAPLUS
CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-[(3R)-6-(3-fluorophenyl)hexahydro-2-oxo-1H-azepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 781648-96-2 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-[(3R)-6-(4-fluorophenyl)hexahydro-2-oxo-1H-azepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 781648-97-3 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-[(3R)-hexahydro-2-oxo-6-(2-pyridinyl)-1H-azepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 781648-98-4 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-


yl)-N-[(3R)-hexahydro-2-oxo-6-(3-pyridinyl)-1H-azepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 781649-00-1 CAPLUS
CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-[(3R)-hexahydro-2-oxo-6-(4-pyridinyl)-1H-azepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 781649-01-2 CAPLUS
CN 1-Piperidinecarboxamide, N-[(3R)-1-(cyclopropylmethyl)hexahydro-6-(3-hydroxyphenyl)-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 781649-02-3 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-1-(cyclopropylmethyl)hexahydro-6-(3-hydroxyphenyl)-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 781649-03-4 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6R)-1-(cyclopropylmethyl)hexahydro-2-oxo-6-(1H-pyrazol-3-yl)-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 781649-04-5 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-1-(cyclopropylmethyl)hexahydro-2-oxo-6-(1H-pyrazol-3-yl)-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 781649-05-6 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-1-[2-(methylthio)ethyl]-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 781649-06-7 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-1-[2-(methylsulfinyl)ethyl]-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 781649-07-8 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-1-[2-(methylsulfonyl)ethyl]-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 781649-08-9 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-1-(2-methoxyethyl)-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 781649-09-0 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-2-oxo-1-(2,2,2-trifluoroethyl)-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 781649-10-3 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-2-oxo-1-(2-pyridinylmethyl)-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 781649-11-4 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-2-oxo-1-(4-pyridinyl)-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 781649-12-5 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-1-methyl-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 781649-13-6 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)-1-ethylhexahydro-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 781649-14-7 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-1-(cyclopropylmethyl)-6-(2,3-difluorophenyl)hexahydro-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 781649-15-8 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)-1-(2-fluoroethyl)hexahydro-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 781649-16-9 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-1-(2,2-difluoroethyl)-6-(2,3-difluorophenyl)hexahydro-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 781649-17-0 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-2-oxo-


1-[[(2R)-tetrahydro-2-furanyl]methyl]-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 781649-18-1 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-2-oxo-1-[[(2S)-tetrahydro-2-furanyl]methyl]-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 781649-19-2 CAPLUS
 CN 1H-Azepine-1-acetic acid, 6-(2,3-difluorophenyl)-3-[[[4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-1-piperidinyl]carbonyl]amino]hexahydro-2-oxo-, methyl ester, (3R,6S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 781649-20-5 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-2-oxo-1-phenyl-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 781649-21-6 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-2-oxo-1-(3-pyridinyl)-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 781649-22-7 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-1-[4-(methylsulfonyl)phenyl]-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 781649-23-8 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-1-[3-(methylsulfonyl)phenyl]-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 781649-24-9 CAPLUS


CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-1-[(6-methoxy-2-pyridinyl)methyl]-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 781649-25-0 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-[hexahydro-1-(2-methoxyethyl)-2-oxo-6-phenyl-1H-azepin-3-yl]- (CA INDEX NAME)




RN 781649-26-1 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-[hexahydro-6-(4-hydroxyphenyl)-2-oxo-1H-azepin-3-yl]- (CA INDEX NAME)




RN 781649-27-2 CAPLUS

CN 1-Piperidinecarboxamide, N-[6-(2,3-difluorophenyl)hexahydro-1-[2-(methylthio)ethyl]-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)




RN 781649-28-3 CAPLUS

CN 1-Piperidinecarboxamide, N-[6-(2,3-difluorophenyl)hexahydro-1-[2-(methylsulfinyl)ethyl]-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)




RN 781649-29-4 CAPLUS

CN 1-Piperidinecarboxamide, N-[6-(2,3-difluorophenyl)hexahydro-1-[2-(methylsulfonyl)ethyl]-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)




RN 781649-30-7 CAPLUS

CN 1-Piperidinecarboxamide, N-[6-(2,3-difluorophenyl)hexahydro-1-(2-methoxyethyl)-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)




RN 781649-31-8 CAPLUS

CN 1-Piperidinecarboxamide, N-[6-(2,3-difluorophenyl)hexahydro-2-oxo-1-(2,2,2-trifluoroethyl)-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)




RN 781649-32-9 CAPLUS

CN 1-Piperidinecarboxamide, N-[6-(2,3-difluorophenyl)hexahydro-2-oxo-1-(2-pyridinylmethyl)-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)




RN 781649-33-0 CAPLUS

CN 1-Piperidinecarboxamide, N-[6-(2,3-difluorophenyl)hexahydro-2-oxo-1-(4-pyridinyl)-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)




RN 781649-34-1 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-(hexahydro-2-oxo-6-phenyl-1H-azepin-3-yl)- (CA INDEX NAME)




RN 781649-35-2 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-(hexahydro-1-methyl-2-oxo-6-phenyl-1H-azepin-3-yl)- (CA INDEX NAME)




RN 781649-36-3 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-(1-ethylhexahydro-2-oxo-6-phenyl-1H-azepin-3-yl)- (CA INDEX NAME)




RN 781649-37-4 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-[hexahydro-2-oxo-6-phenyl-1-(2,2,2-trifluoroethyl)-1H-azepin-3-yl]- (CA INDEX NAME)




RN 781649-38-5 CAPLUS

CN 1H-Azepine-1-acetic acid, 3-[[[4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-1-piperidinyl]carbonyl]amino]hexahydro-2-oxo-6-phenyl-, methyl ester (CA INDEX NAME)




RN 781649-39-6 CAPLUS

CN 1H-Azepine-1-acetic acid, 3-[[[4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-1-piperidinyl]carbonyl]amino]hexahydro-2-oxo-6-phenyl- (CA INDEX NAME)




RN 781649-40-9 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-[1-(2-ethoxyethyl)hexahydro-2-oxo-6-phenyl-1H-azepin-3-yl]- (CA INDEX NAME)



RN 781649-41-0 CAPLUS


CN 1-Piperidinecarboxamide, N-[1-(cyanomethyl)hexahydro-2-oxo-6-phenyl-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)



RN 781649-42-1 CAPLUS


CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-[hexahydro-1-(2-hydroxyethyl)-2-oxo-6-phenyl-1H-azepin-3-yl]- (CA INDEX NAME)

INDEX NAME)




RN 781649-43-2 CAPLUS

CN 1-Piperidinecarboxamide, N-[1-(cyclopropylmethyl)hexahydro-2-oxo-6-phenyl-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)




RN 781649-44-3 CAPLUS

CN 1H-Azepine-1-acetamide, 3-[[[4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-1-piperidinyl]carbonyl]amino]hexahydro-N,N-dimethyl-2-oxo-6-phenyl- (CA INDEX NAME)




RN 781649-45-4 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-[6-(2-fluorophenyl)hexahydro-2-oxo-1H-azepin-3-yl]- (CA INDEX NAME)




RN 781649-46-5 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-[6-(3-fluorophenyl)hexahydro-2-oxo-1H-azepin-3-yl]- (CA INDEX NAME)




RN 781649-47-6 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-[6-(4-fluorophenyl)hexahydro-2-oxo-1H-azepin-3-yl]- (CA INDEX NAME)




RN 781649-48-7 CAPLUS

CN 1-Piperidinecarboxamide, N-[6-(2,3-difluorophenyl)hexahydro-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)




RN 781649-49-8 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-[hexahydro-2-oxo-6-(2-pyridinyl)-1H-azepin-3-yl]- (CA INDEX NAME)




RN 781649-50-1 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-[hexahydro-2-oxo-6-(3-pyridinyl)-1H-azepin-3-yl]- (CA INDEX NAME)




RN 781649-51-2 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-[hexahydro-2-oxo-6-(4-pyridinyl)-1H-azepin-3-yl]- (CA INDEX NAME)




RN 781649-52-3 CAPLUS

CN 1-Piperidinecarboxamide, N-[1-(cyclopropylmethyl)hexahydro-6-(3-hydroxyphenyl)-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)



RN 781649-53-4 CAPLUS


CN 1-Piperidinecarboxamide, N-[1-(cyclopropylmethyl)hexahydro-2-oxo-6-(1H-pyrazol-3-yl)-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)



RN 781649-54-5 CAPLUS


CN 1-Piperidinecarboxamide, N-[6-(2,3-difluorophenyl)hexahydro-1-methyl-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)

1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA
INDEX NAME)




RN 781649-55-6 CAPLUS

CN 1-Piperidinecarboxamide, N-[6-(2,3-difluorophenyl)-1-ethylhexahydro-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA
INDEX NAME)




RN 781649-56-7 CAPLUS

CN 1-Piperidinecarboxamide, N-[1-(cyclopropylmethyl)-6-(2,3-difluorophenyl)hexahydro-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)




RN 781649-57-8 CAPLUS

CN 1-Piperidinecarboxamide, N-[6-(2,3-difluorophenyl)-1-(2-fluoroethyl)hexahydro-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)




RN 781649-58-9 CAPLUS

CN 1-Piperidinecarboxamide, N-[1-(2,2-difluoroethyl)-6-(2,3-difluorophenyl)hexahydro-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)




RN 781649-59-0 CAPLUS

CN 1-Piperidinecarboxamide, N-[6-(2,3-difluorophenyl)hexahydro-2-oxo-1-[(tetrahydro-2-furanyl)methyl]-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)




RN 781649-60-3 CAPLUS

CN 1H-Azepine-1-acetic acid, 6-(2,3-difluoro-2,4-cyclohexadien-1-yl)-3-[[[4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-1-piperidinyl]carbonyl]amino]hexahydro-2-oxo-, methyl ester (CA INDEX NAME)




RN 781649-61-4 CAPLUS

CN 1-Piperidinecarboxamide, N-[6-(2,3-difluorophenyl)hexahydro-2-oxo-1-phenyl-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)




RN 781649-63-6 CAPLUS

CN 1-Piperidinecarboxamide, N-[6-(2,3-difluorophenyl)hexahydro-2-oxo-1-(3-pyridinyl)-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)



RN 781649-64-7 CAPLUS


CN 1-Piperidinecarboxamide, N-[6-(2,3-difluorophenyl)hexahydro-1-[4-(methylsulfonyl)phenyl]-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)



RN 781649-66-9 CAPLUS


CN 1-Piperidinecarboxamide, N-[6-(2,3-difluorophenyl)hexahydro-1-[3-

(methylsulfonyl)phenyl]-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)



RN 781649-68-1 CAPLUS


CN 1-Piperidinecarboxamide, N-[6-(2,3-difluorophenyl)hexahydro-1-[(6-methoxy-2-pyridinyl)methyl]-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)



RN 781649-69-2 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-[(3R,6S)-hexahydro-6-(4-hydroxyphenyl)-2-oxo-1H-azepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 781649-70-5 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-[(3R,6S)-6-(2-fluorophenyl)hexahydro-2-oxo-1H-azepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 781649-72-7 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-[(3R,6S)-6-(3-fluorophenyl)hexahydro-2-oxo-1H-azepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 781649-74-9 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-[(3R,6R)-hexahydro-2-oxo-6-(2-pyridinyl)-1H-azepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 781649-76-1 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-[(3R,6S)-6-(4-fluorophenyl)hexahydro-2-oxo-1H-azepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 781649-78-3 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 781649-80-7 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-


yl)-N-[(3R,6S)-hexahydro-2-oxo-6-(3-pyridinyl)-1H-azepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 781649-82-9 CAPLUS
CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-[(3R,6S)-hexahydro-2-oxo-6-(4-pyridinyl)-1H-azepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 781650-61-1 CAPLUS
CN 1-Piperidinecarboxamide, N-[(3R)-6-(2,3-difluorophenyl)hexahydro-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)



Absolute stereochemistry.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 17 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2004:902376 CAPLUS Full-text
 DN 141:379816
 TI Preparation of piperidine derivatives as CGRP receptor antagonists
 IN Burgey, Christopher S.; Deng, Zhengwu J.; Nguyen, Diem N.; Paone, Daniel
 V.; Shaw, Anthony W.; Williams, Theresa M.
 PA Merck & Co., Inc., USA
 SO PCT Int. Appl., 200 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004092166	A2	20041028	WO 2004-US10851	20040409
	WO 2004092166	A3	20050120		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				
	CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,				
	GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,				
	LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,				
	NO, NZ, OM, PG, PH, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,				
	TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,				
	BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,				
	ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,				
	SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,				
	TD, TG				
	AU 2004230926	A1	20041028	AU 2004-230926	20040409
	CA 2522220	A1	20041028	CA 2004-2522220	20040409
	EP 1638969	A2	20060329	EP 2004-749887	20040409
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
	CN 1802376	A	20060712	CN 2004-80016115	20040409
	JP 2006523697	T	20061019	JP 2006-509818	20040409
	JP 3967766	B2	20070829		
	US 2004229861	A1	20041118	US 2004-838835	20040504
	US 6953790	B2	20051011		
	US 2005256098	A1	20051117	US 2005-152537	20050614
	US 7235545	B2	20070626		
	US 2007225272	A1	20070927	US 2007-724066	20070314
PRAI	US 2003-463089P	P	20030415		
	US 2003-510352P	P	20031010		
	WO 2004-US10851	W	20040409		
	US 2004-838835	A1	20040504		
	US 2005-152537	A1	20050614		
OS	MARPAT 141:379816				
GI					



AB Title compds. I [Z = -(CR₂₂)₂A- or -BCR₂:CR₂-, wherein A = bond, CR₂₂, O, S(O)_m or NR₂; m = 0-2; B = (CR₂₂)_n; n = 0-1; R₁ = H, (un)substituted-alkyl, -alkenyl, -alkynyl, -aryl, etc.; R₂ = H, (un)substituted-alkyl, -alkenyl, -alkynyl, -cycloalkyl, -aryl, -heteroaryl, etc., or any two independent R₂ on the same or adjacent atoms may be joined together to form a ring; R₃ = H, F, CN, (un)substituted-alkyl, etc.; R₄ = H, (un)substituted-alkyl, -cycloalkyl, -aryl, etc.; W = O, NR₄ or CR₄₂; X = C or S; Y = O, R₄₂, NCN, NSO₂Me, NCONH₂, or Y = O₂ when X = S; G-J = N, NCR₅₂, C:CR₅, C:N, CR₅, etc.; R₅ = H, CN, OR₄, etc.; Q, T, U and V independently = C or N wherein at least one but no more than three of Q, T, U, and V = N, of which one may be optionally an N-oxide, and wherein any of Q, T, U, or V = C, C may be optionally substituted with R₆; R₆ = H, alkyl, cycloalkyl, halo, CO₂R₄, etc.], as well as their pharmaceutically acceptable salts, are prepared and disclosed as antagonists of CGRP receptors. Thus, e.g., II was prepared via acylation of (3R,6S)-3-amino-1-(2-methoxyethyl)-6-phenylazepan-2-one (preparation given) with p-nitrophenylchloroformate and subsequent reaction with 2-oxo-1-(4-piperidinyl)-2,3-dihydro-1H-imidazo[4,5-b]pyridine dihydrochloride (preparation given). I had activity as antagonists of the CGRP receptor, as determined by described assays, with K_i or IC₅₀ values of generally less than 50 μM. I are useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compns. comprising these compds. and the use of these compds. and compns. in the prevention or treatment of such diseases in which CGRP is involved.

IT 781648-80-4P 781648-81-5P 781648-82-6P
 781648-83-7P 781648-84-8P 781648-85-9P
 781648-86-0P 781648-87-1P 781648-88-2P
 781648-89-3P 781648-90-6P 781648-91-7P
 781648-92-8P 781648-93-9P 781648-94-0P
 781648-95-1P 781648-96-2P 781648-97-3P
 781648-98-4P 781649-00-1P 781649-01-2P
 781649-02-3P 781649-03-4P 781649-04-5P
 781649-05-6P 781649-06-7P 781649-07-8P
 781649-08-9P 781649-09-0P 781649-10-3P
 781649-11-4P 781649-12-5P 781649-13-6P
 781649-14-7P 781649-15-8P 781649-16-9P
 781649-17-0P 781649-18-1P 781649-19-2P
 781649-20-5P 781649-21-6P 781649-22-7P
 781649-23-8P 781649-24-9P 781649-70-5P

781650-61-1P 784153-82-8P 784153-83-9P
 784153-84-0P 784153-85-1P 784153-86-2P
 784153-87-3P 784153-88-4P 784153-89-5P
 784153-90-8P 784153-91-9P 784153-92-0P
 784153-93-1P 784153-94-2P 784153-95-3P
 784153-96-4P 784153-97-5P 784153-98-6P
 784153-99-7P 784154-00-3P 784154-01-4P
 784154-02-5P 784154-07-0P 784154-08-1P
 784154-09-2P 784154-10-5P 784154-11-6P
 784154-12-7P 784154-13-8P 784154-14-9P
 784154-15-0P 784154-16-1P 784154-17-2P
 784154-20-7P 784154-21-8P 784154-22-9P
 784154-23-0P 784154-24-1P 784154-25-2P
 784154-26-3P 784154-27-4P 784154-28-5P
 784154-29-6P 784154-30-9P 784154-31-0P
 784154-32-1P 784154-35-4P 784154-36-5P
 784154-37-6P 784154-38-7P 784154-39-8P
 784154-40-1P 784154-41-2P 784154-42-3P
 784154-43-4P 784154-44-5P 784154-45-6P
 784154-46-7P 784154-47-8P 784154-48-9P
 784154-49-0P 784154-50-3P 784154-51-4P
 784154-52-5P 784154-53-6P 784154-54-7P
 784154-55-8P 784154-56-9P 784154-57-0P
 784154-58-1P 784154-59-2P 784154-60-5P
 784154-61-6P 784154-62-7P 784154-63-8P
 784154-64-9P 784154-65-0P 784154-66-1P
 784154-67-2P 784154-68-3P 784154-69-4P
 784154-70-7P 784154-71-8P 784154-72-9P
 784154-73-0P 784154-74-1P 784154-75-2P
 784154-76-3P 784154-77-4P 784154-78-5P
 784154-79-6P 784154-80-9P 784154-81-0P
 784154-82-1P 784154-83-2P 784154-84-3P
 784154-85-4P 784154-86-5P 784154-87-6P
 784154-88-7P 784154-89-8P 784154-90-1P
 784154-91-2P 784154-92-3P 784154-93-4P
 784154-94-5P 784154-95-6P 784154-96-7P
 784154-97-8P 784154-98-9P 784154-99-0P
 784155-00-6P 784155-01-7P 784155-02-8P
 784155-03-9P 784155-04-0P 784155-05-1P
 784155-06-2P 784155-07-3P 784155-08-4P
 784155-09-5P 784155-11-9P 784155-13-1P
 784155-15-3P 784155-17-5P 784155-19-7P
 784155-21-1P 784155-23-3P 784155-24-4P
 784155-25-5P 784155-26-6P 784155-27-7P
 784155-28-8P 784155-29-9P 784155-30-2P
 784156-98-5P 784156-99-6P 784157-00-2P
 784157-01-3P 784157-02-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of heterocyclic substituted piperidine derivs. as CGRP
 receptor
 antagonists)

RN 781648-80-4 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-
 yl)-N-[(3R,6S)-hexahydro-1-(2-methoxyethyl)-2-oxo-6-phenyl-1H-azepin-3-yl]-
 (CA INDEX NAME)


Absolute stereochemistry.



RN 781648-81-5 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-[(3R,6S)-hexahydro-2-oxo-6-phenyl-1H-azepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 781648-82-6 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-[(3R,6R)-hexahydro-2-oxo-6-phenyl-1H-azepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 781648-83-7 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-[(3R,6S)-hexahydro-1-methyl-2-oxo-6-phenyl-1H-azepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 781648-84-8 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-[(3R,6S)-1-ethylhexahydro-2-oxo-6-phenyl-1H-azepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 781648-85-9 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-[(3R,6S)-hexahydro-2-oxo-6-phenyl-1-(2,2,2-trifluoroethyl)-1H-azepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 781648-86-0 CAPLUS

CN 1H-Azepine-1-acetic acid, 3-[[[4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-1-piperidinyl]carbonyl]amino]hexahydro-2-oxo-6-phenyl-, (CA INDEX NAME)

methyl ester, (3R,6S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 781648-87-1 CAPLUS

CN 1H-Azepine-1-acetic acid, 3-[[[4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-1-piperidinyl]carbonyl]amino]hexahydro-2-oxo-6-phenyl-, (3R,6S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 781648-88-2 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-[(3R,6S)-1-(2-ethoxyethyl)hexahydro-2-oxo-6-phenyl-1H-azepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 781648-89-3 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-1-(cyanomethyl)hexahydro-2-oxo-6-phenyl-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-
(CA INDEX NAME)


Absolute stereochemistry.



RN 781648-90-6 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-[(3R,6S)-hexahydro-1-(2-hydroxyethyl)-2-oxo-6-phenyl-1H-azepin-3-yl]-
(CA INDEX NAME)


Absolute stereochemistry.



RN 781648-91-7 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-1-(cyclopropylmethyl)hexahydro-2-oxo-6-phenyl-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-
(CA INDEX NAME)


Absolute stereochemistry.



RN 781648-92-8 CAPLUS

CN 1H-Azepine-1-acetamide, 3-[[[4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-1-piperidinyl]carbonyl]amino]hexahydro-N,N-dimethyl-2-oxo-6-phenyl-, (3R,6S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 781648-93-9 CAPLUS


CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-[(3R)-hexahydro-6-(4-hydroxyphenyl)-2-oxo-1H-azepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 781648-94-0 CAPLUS
CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-[(3R)-6-(2-fluorophenyl)hexahydro-2-oxo-1H-azepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 781648-95-1 CAPLUS
CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-[(3R)-6-(3-fluorophenyl)hexahydro-2-oxo-1H-azepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 781648-96-2 CAPLUS
CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-[(3R)-6-(4-fluorophenyl)hexahydro-2-oxo-1H-azepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 781648-97-3 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-[(3R)-hexahydro-2-oxo-6-(2-pyridinyl)-1H-azepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 781648-98-4 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-[(3R)-hexahydro-2-oxo-6-(3-pyridinyl)-1H-azepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 781649-00-1 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-[(3R)-hexahydro-2-oxo-6-(4-pyridinyl)-1H-azepin-3-yl]- (CA INDEX NAME)

yl)-N-[(3R)-hexahydro-2-oxo-6-(4-pyridinyl)-1H-azepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 781649-01-2 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R)-1-(cyclopropylmethyl)hexahydro-6-(3-hydroxyphenyl)-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 781649-02-3 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-1-(cyclopropylmethyl)hexahydro-6-(3-hydroxyphenyl)-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 781649-03-4 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6R)-1-(cyclopropylmethyl)hexahydro-2-oxo-6-(1H-pyrazol-3-yl)-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 781649-04-5 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-1-(cyclopropylmethyl)hexahydro-2-oxo-6-(1H-pyrazol-3-yl)-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 781649-05-6 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-1-[2-(methylthio)ethyl]-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 781649-06-7 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-1-[2-(methylsulfinyl)ethyl]-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 781649-07-8 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-1-[2-(methylsulfonyl)ethyl]-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 781649-08-9 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-1-(2-methylsulfonyl)ethyl]-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)

methoxyethyl)-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 781649-09-0 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-2-oxo-1-(2,2,2-trifluoroethyl)-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 781649-10-3 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-2-oxo-1-(2-pyridinylmethyl)-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 781649-11-4 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-2-oxo-1-(4-pyridinyl)-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 781649-12-5 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-1-methyl-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 781649-13-6 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)-1-ethylhexahydro-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 781649-14-7 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-1-(cyclopropylmethyl)-6-(2,3-difluorophenyl)hexahydro-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 781649-15-8 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)-1-(2-fluoroethyl)hexahydro-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 781649-16-9 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-1-(2,2-difluoroethyl)-6-(2,3-difluorophenyl)hexahydro-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 781649-17-0 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-2-oxo-1-[(2R)-tetrahydro-2-furanyl)methyl]-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 781649-18-1 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-2-oxo-1-[[(2S)-tetrahydro-2-furanyl]methyl]-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 781649-19-2 CAPLUS

CN 1H-Azepine-1-acetic acid, 6-(2,3-difluorophenyl)-3-[[[4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-1-piperidinyl]carbonyl]amino]hexahydro-2-oxo-, methyl ester, (3R,6S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 781649-20-5 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-2-oxo-1-phenyl-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 781649-21-6 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-2-oxo-1-(3-pyridinyl)-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 781649-22-7 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-1-[4-(methylsulfonyl)phenyl]-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 781649-23-8 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-1-[3-(methylsulfonyl)phenyl]-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 781649-24-9 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-1-[(6-methoxy-2-pyridinyl)methyl]-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 781649-70-5 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-[(3R,6S)-6-(2-fluorophenyl)hexahydro-2-oxo-1H-azepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 781650-61-1 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R)-6-(2,3-difluorophenyl)hexahydro-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 784153-82-8 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-[(3R,6S)-1-(1,3-dioxolan-2-ylmethyl)hexahydro-2-oxo-6-phenyl-1H-azepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 784153-83-9 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-[(3R,6S)-1-(2-fluoroethyl)hexahydro-2-oxo-6-phenyl-1H-azepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 784153-84-0 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-1-(2,2-difluoroethyl)hexahydro-2-oxo-6-phenyl-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 784153-85-1 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-1-(3,3-difluoro-2-propenyl)hexahydro-2-oxo-6-phenyl-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 784153-86-2 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-[(3R,6S)-hexahydro-2-oxo-6-phenyl-1-(phenylmethyl)-1H-azepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 784153-87-3 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-

yl)-N-[(3R,6S)-hexahydro-2-oxo-6-phenyl-1-(2-pyridinylmethyl)-1H-azepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 784153-88-4 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-[(3R,6S)-hexahydro-2-oxo-6-phenyl-1-[(2R)-tetrahydro-2-furanyl]methyl]-1H-azepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 784153-89-5 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-[(3R,6S)-hexahydro-2-oxo-6-phenyl-1-[(2S)-tetrahydro-2-furanyl]methyl]-1H-azepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 784153-90-8 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-1-(2-aminoethyl)hexahydro-2-oxo-6-phenyl-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-
(CA INDEX NAME)


Absolute stereochemistry.



RN 784153-91-9 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-[(3R,6S)-hexahydro-1-[2-(1-methylethoxy)ethyl]-2-oxo-6-phenyl-1H-azepin-3-yl]-
(CA INDEX NAME)


Absolute stereochemistry.



RN 784153-92-0 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-[(3R,6S)-hexahydro-1-(3-methoxypropyl)-2-oxo-6-phenyl-1H-azepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 784153-93-1 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-[(3R,6S)-hexahydro-1-[2-(methylthio)ethyl]-2-oxo-6-phenyl-1H-azepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 784153-94-2 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-[(3R,6S)-hexahydro-1-[2-(methylsulfonyl)ethyl]-2-oxo-6-phenyl-1H-azepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 784153-95-3 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-[(3R,6S)-hexahydro-2-oxo-6-phenyl-1-[2-(trifluoromethoxy)ethyl]-1H-azepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 784153-96-4 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-1-[2-(cyclopropyloxy)ethyl]hexahydro-2-oxo-6-phenyl-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 784153-97-5 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-[(3R,6S)-hexahydro-1-(2-hydroxypropyl)-2-oxo-6-phenyl-1H-azepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 784153-98-6 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-[(3R,6S)-hexahydro-1-(2-hydroxy-2-methylpropyl)-2-oxo-6-phenyl-1H-azepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 784153-99-7 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-1-(2-aminopropyl)hexahydro-2-oxo-6-phenyl-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 784154-00-3 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-[(3R,6S)-hexahydro-2-oxo-6-phenyl-1-(3,3,3-trifluoro-2-hydroxypropyl)-1H-azepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 784154-01-4 CAPLUS


CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-[(3R,6S)-hexahydro-2-oxo-6-phenyl-1-[(tetrahydro-3-furanyl)methyl]-1H-azepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 784154-02-5 CAPLUS
CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-[(3R,6S)-hexahydro-2-oxo-1,6-diphenyl-1H-azepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 784154-07-0 CAPLUS
CN 1-Piperidinecarboxamide, N-[(3R,6R)-6-(2,3-difluorophenyl)hexahydro-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 784154-08-1 CAPLUS
CN 1-Piperidinecarboxamide, N-[(3R)-6-(3,5-difluorophenyl)hexahydro-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 784154-09-2 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R)-6-(2,5-difluorophenyl)hexahydro-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 784154-10-5 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-[(3R)-hexahydro-2-oxo-6-[2-(trifluoromethyl)phenyl]-1H-azepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 784154-11-6 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-[(3R)-hexahydro-6-(2-methylphenyl)-2-oxo-1H-azepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 784154-12-7 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-[(3R)-hexahydro-6-(3-methylphenyl)-2-oxo-1H-azepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 784154-13-8 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-[(3R)-hexahydro-6-(4-methylphenyl)-2-oxo-1H-azepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 784154-14-9 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R)-6-(2-chlorophenyl)hexahydro-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 784154-15-0 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2-chlorophenyl)hexahydro-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 784154-16-1 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R)-6-(3-chlorophenyl)hexahydro-2-oxo-1H-


azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA
INDEX NAME)

Absolute stereochemistry.




RN 784154-17-2 CAPLUS
CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-[(3R)-hexahydro-6-(1-methylethyl)-2-oxo-1H-azepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 784154-20-7 CAPLUS
CN 1-Piperidinecarboxamide, N-[(3R)-6-(2,3-dichlorophenyl)hexahydro-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 784154-21-8 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R)-6-cyclohexylhexahydro-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 784154-22-9 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-[(3R)-hexahydro-2-oxo-6-(phenylmethyl)-1H-azepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 784154-23-0 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R)-6-(3-chloro-2-fluorophenyl)hexahydro-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 784154-24-1 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-[(3R,6S)-1-ethyl-6-(2-fluorophenyl)hexahydro-2-oxo-1H-azepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 784154-25-2 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-[(3R,6S)-1-(2-fluoroethyl)-6-(3-fluorophenyl)hexahydro-2-oxo-1H-azepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 784154-26-3 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-

yl)-N-[(3R,6S)-6-(3-fluorophenyl)hexahydro-1-(2-methoxyethyl)-2-oxo-1H-azepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 784154-27-4 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-[(3R)-1-ethylhexahydro-2-oxo-6-(phenylmethyl)-1H-azepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 784154-28-5 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R)-6-(2,3-dichlorophenyl)hexahydro-1-methyl-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 784154-29-6 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-dichlorophenyl)hexahydro-1-methyl-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 784154-30-9 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-dichlorophenyl)-1-ethylhexahydro-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 784154-31-0 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R)-6-(3-chloro-2-fluorophenyl)-1-ethylhexahydro-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 784154-32-1 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R)-6-(2,3-dichlorophenyl)hexahydro-2-oxo-1-(2,2,2-trifluoroethyl)-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 784154-35-4 CAPLUS

CN 1-Piperidinecarboxamide, N-[(2S,6R)-4-(cyclopropylmethyl)hexahydro-5-oxo-2-phenyl-1,4-oxazepin-6-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 784154-36-5 CAPLUS

CN 1-Piperidinecarboxamide, N-[(2S,6R)-2-(2,3-difluorophenyl)hexahydro-5-oxo-4-(2,2,2-trifluoroethyl)-1,4-oxazepin-6-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 784154-37-6 CAPLUS

CN Piperidine, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-1-[[(3R,6R)-hexahydro-1-(2-methoxyethyl)-2-oxo-6-phenyl-1H-azepin-3-yl]acetyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 784154-38-7 CAPLUS

CN Piperidine, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-1-[[(3R,6S)-hexahydro-1-(2-methoxyethyl)-2-oxo-6-phenyl-1H-azepin-3-yl]acetyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 784154-39-8 CAPLUS

CN Piperidine, 1-[[(3R,6S)-1-(cyclopropylmethyl)hexahydro-2-oxo-6-phenyl-1H-azepin-3-yl]acetyl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 784154-40-1 CAPLUS


CN Piperidine, 1-[[(3S,6R)-1-(cyclopropylmethyl)hexahydro-2-oxo-6-phenyl-1H-azepin-3-yl]acetyl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 784154-41-2 CAPLUS
CN Piperidine, 1-[[(3R,6R)-1-(cyclopropylmethyl)hexahydro-2-oxo-6-phenyl-1H-azepin-3-yl]acetyl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 784154-42-3 CAPLUS
CN Piperidine, 1-[[(3S,6S)-1-(cyclopropylmethyl)hexahydro-2-oxo-6-phenyl-1H-azepin-3-yl]acetyl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 784154-43-4 CAPLUS
CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-2-oxo-1-(2-thiazolylmethyl)-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-(CA INDEX NAME)


Absolute stereochemistry.



RN 784154-44-5 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-1-(2-hydroxy-2-methylpropyl)-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 784154-45-6 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-1-(3-isoxazolylmethyl)-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 784154-46-7 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-1-(1-isoxazolylmethyl)-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)

methylethyl)-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 784154-47-8 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-1-[(1-methyl-1H-imidazol-2-yl)methyl]-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 784154-48-9 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-1-[(1-methyl-1H-pyrazol-3-yl)methyl]-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 784154-49-0 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-1-[(1-methyl-1H-pyrazol-5-yl)methyl]-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 784154-50-3 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-2-oxo-1-[1-(2-thiazolyl)ethyl]-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 784154-51-4 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-2-oxo-1-(3-pyridinylmethyl)-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 784154-52-5 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-2-oxo-1-(4-pyridinylmethyl)-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 784154-53-6 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-1-[2-(1-methylethoxy)ethyl]-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 784154-54-7 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-1-(3-methoxypropyl)-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 784154-55-8 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-1-[2-(cyclopropyloxy)ethyl]-6-(2,3-difluorophenyl)hexahydro-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 784154-56-9 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-2-oxo-


1-[2-(trifluoromethoxy)ethyl]-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 784154-57-0 CAPLUS
 CN 1H-Azepine-1-acetic acid, 6-(2,3-difluorophenyl)-3-[[[4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-1-piperidinyl]carbonyl]amino]hexahydro-2-oxo-, (3R,6S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 784154-58-1 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-1-[(1-oxido-2-pyridinyl)methyl]-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 784154-59-2 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-2-oxo-1-[2-(1-pyrrolidinyl)ethyl]-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 784154-60-5 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-1-[2-(4-morpholinyl)ethyl]-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 784154-61-6 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)-1-[2-(dimethylamino)ethyl]hexahydro-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 784154-62-7 CAPLUS

CN 1H-Azepine-1-acetic acid, 6-(2,3-difluorophenyl)-3-[[[4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-1-piperidiny]carbonyl]amino]hexahydro-2-oxo-, 1-methylethyl ester, (3R,6S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 784154-63-8 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-1-(2-aminoethyl)-6-(2,3-difluorophenyl)hexahydro-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 784154-64-9 CAPLUS

CN Pentitol, 1,4-anhydro-2,3,5-trideoxy-3-[(3R,6S)-6-(2,3-difluorophenyl)-3-[[[4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-1-piperidinyl]carbonyl]amino]hexahydro-2-oxo-1H-azepin-1-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 784154-65-0 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-2-oxo-1-[2-(1-piperidinyl)ethyl]-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 784154-66-1 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-2-oxo-1-(3-pyrrolidinyl)-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 784154-67-2 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-2-oxo-1-(tetrahydro-3-furanyl)-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 784154-68-3 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-1-[2-(methylamino)ethyl]-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 784154-69-4 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-1-[2-(4-methyl-1-piperazinyl)ethyl]-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 784154-70-7 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-1-(2-methoxypropyl)-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 784154-71-8 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-2-oxo-1-(3,3,3-trifluoropropyl)-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 784154-72-9 CAPLUS

CN 1H-Azepine-1-propanoic acid, 6-(2,3-difluorophenyl)-3-[[[4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-1-piperidinyl]carbonyl]amino]hexahydro- α -methyl-2-oxo-, methyl ester, (α S,3R,6S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 784154-73-0 CAPLUS

CN 1H-Azepine-1-propanoic acid, 6-(2,3-difluorophenyl)-3-[[[4-(2,3-dihydro-2-

oxo-1H-imidazo[4,5-b]pyridin-1-yl)-1-piperidinyl]carbonyl]amino]hexahydro-
 α -methyl-2-oxo-, (α S,3R,6S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 784154-74-1 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-2-oxo-1-(2-pyrimidinylmethyl)-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 784154-75-2 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-1-[[[(2S)-1-acetyl-2-pyrrolidinyl]methyl]-6-(2,3-difluorophenyl)hexahydro-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 784154-76-3 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-2-oxo-1-[(2S)-1-(2,2,2-trifluoroethyl)-2-pyrrolidinylmethyl]-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 784154-77-4 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-2-oxo-1-[(2S)-2-pyrrolidinylmethyl]-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 784154-78-5 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)-1-[(3-fluoro-2-pyridinyl)methyl]hexahydro-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 784154-79-6 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-1-[[(2S)-1-methyl-2-pyrrolidinyl]methyl]-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 784154-80-9 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-1-(2-hydroxyethyl)-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 784154-81-0 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-2-oxo-1-(3,3,3-trifluoro-2-hydroxypropyl)-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 784154-82-1 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-2-oxo-1-(3,3,3-trifluoro-2-oxopropyl)-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 784154-83-2 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-1-(2-

hydroxypropyl)-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 784154-84-3 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-2-oxo-1-(3,3,3-trifluoro-2-methoxypropyl)-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 784154-85-4 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-2-oxo-1-(2-oxopropyl)-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 784154-86-5 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-2-oxo-1-(2,2,2-trifluoroethyl)-1H-azepin-3-yl]-4-(1,8-dihydro-8-oxo-7H-purin-7-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 784154-87-6 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-1-methyl-2-oxo-1H-azepin-3-yl]-4-(1,8-dihydro-8-oxo-7H-purin-7-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 784154-88-7 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-1-(cyclopropylmethyl)-6-(2,3-difluorophenyl)hexahydro-2-oxo-1H-azepin-3-yl]-4-(1,8-dihydro-8-oxo-7H-purin-7-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 784154-89-8 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R, 6S)-1-(2,2-difluoroethyl)-6-(2,3-difluorophenyl)hexahydro-2-oxo-1H-azepin-3-yl]-4-(1,8-dihydro-8-oxo-7H-purin-7-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 784154-90-1 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R, 6S)-6-(2,3-difluorophenyl)hexahydro-2-oxo-1-[2-(trifluoromethoxy)ethyl]-1H-azepin-3-yl]-4-(1,8-dihydro-8-oxo-7H-purin-7-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 784154-91-2 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R, 6S)-6-(2,3-difluorophenyl)hexahydro-1-[2-

(methylthio)ethyl]-2-oxo-1H-azepin-3-yl]-4-(1,8-dihydro-8-oxo-7H-purin-7-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 784154-92-3 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-1-[2-(methylsulfinyl)ethyl]-2-oxo-1H-azepin-3-yl]-4-(1,8-dihydro-8-oxo-7H-purin-7-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 784154-93-4 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-1-[2-(methylsulfonyl)ethyl]-2-oxo-1H-azepin-3-yl]-4-(1,8-dihydro-8-oxo-7H-purin-7-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 784154-94-5 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-1-(2-methoxyethyl)-2-oxo-1H-azepin-3-yl]-4-(1,8-dihydro-8-oxo-7H-purin-7-yl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 784154-95-6 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-1-(2-hydroxyethyl)-2-oxo-1H-azepin-3-yl]-4-(1,8-dihydro-8-oxo-7H-purin-7-yl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 784154-96-7 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-2-oxo-1-phenyl-1H-azepin-3-yl]-4-(1,8-dihydro-8-oxo-7H-purin-7-yl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 784154-97-8 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-2-oxo-1-(3,3,3-trifluoro-2-methoxypropyl)-1H-azepin-3-yl]-4-(1,8-dihydro-8-oxo-7H-purin-7-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 784154-98-9 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,8-dihydro-8-oxo-7H-purin-7-yl)-N-[(3R,6S)-hexahydro-2-oxo-6-phenyl-1-(2,2,2-trifluoroethyl)-1H-azepin-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 784154-99-0 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyrazin-1-yl)-N-[(3R,6S)-6-phenylhexahydro-2-oxo-1-(2,2,2-trifluoroethyl)-1H-azepin-3-yl]- (9CI) (CA INDEX NAME)

yl)-N-[(3R,6S)-hexahydro-2-oxo-6-phenyl-1-(2,2,2-trifluoroethyl)-1H-azepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 784155-00-6 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-1-(2-methoxyethyl)-2-oxo-1H-azepin-3-yl]-4-(1,6-dihydro-6-oxo-5H-imidazo[4,5-c]pyridazin-5-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 784155-01-7 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-1-(2-methoxyethyl)-2-oxo-1H-azepin-3-yl]-4-(1,4-dihydro-2-oxopyrido[3,4-d]pyrimidin-3(2H)-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 784155-02-8 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-1-(2-methoxyethyl)-2-oxo-1H-azepin-3-yl]-4-(1,4-dihydro-2-oxopyrido[4,3-d]pyrimidin-3(2H)-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 784155-03-9 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-1-(2-methoxyethyl)-2-oxo-1H-azepin-3-yl]-4-(1,4-dihydro-2-oxopyrido[2,3-d]pyrimidin-3(2H)-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 784155-04-0 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-2-oxo-1-(2,2,2-trifluoroethyl)-1H-azepin-3-yl]-4-(2,3-dihydro-5-methoxy-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 784155-05-1 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-1-(2-hydroxy-2-methylpropyl)-2-oxo-1H-azepin-3-yl]-4-(6-fluoro-2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 784155-06-2 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-2-oxo-1-(2,2,2-trifluoroethyl)-1H-azepin-3-yl]-4-(2,3-dihydro-4-oxido-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 784155-07-3 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-1-methyl-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-4-oxo-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 784155-08-4 CAPLUS

CN 1-Piperidinecarboximidamide, N-cyano-N'-[(3R,6S)-6-(2,3-difluorophenyl)-1-ethylhexahydro-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 784155-09-5 CAPLUS


CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-7-(hydroxymethyl)-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 784155-11-9 CAPLUS

CN 1-Piperidinecarboxamide, N-[5-(2,3-difluorophenyl)-1-(2-methoxyethyl)-2-oxo-3-piperidinyl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)




RN 784155-13-1 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-[1-(2-methoxyethyl)-2-oxo-5-phenyl-3-piperidinyl]- (CA INDEX NAME)




RN 784155-15-3 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-(1-methyl-2-oxo-5-phenyl-3-piperidinyl)- (CA INDEX NAME)




RN 784155-17-5 CAPLUS

CN 1-Piperidinecarboxamide, N-[5-(2,3-difluorophenyl)-1-methyl-2-oxo-3-piperidinyl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)




RN 784155-19-7 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-[2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-3-piperidinyl]- (CA INDEX NAME)



RN 784155-21-1 CAPLUS


CN 1-Piperidinecarboxamide, N-[5-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)-3-piperidinyl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)



RN 784155-23-3 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-[(3R,5R)-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-3-piperidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 784155-24-4 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-[(3R,5S)-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-3-piperidinyl]-
(CA INDEX NAME)


Absolute stereochemistry.



RN 784155-25-5 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-[(3S,5R)-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-3-piperidinyl]-
(CA INDEX NAME)

Absolute stereochemistry.




RN 784155-26-6 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-


yl)-N-[(3S,5S)-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-3-piperidiny]-
(CA INDEX NAME)

Absolute stereochemistry.




RN 784155-27-7 CAPLUS

CN 1-Piperidinecarboxamide, N-[1-[(2,3-difluorophenyl)methyl]hexahydro-5-oxo-4-(2,2,2-trifluoroethyl)-1H-1,4-diazepin-6-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)- (CA INDEX NAME)




RN 784155-28-8 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-[hexahydro-5-oxo-1-(phenylmethyl)-4-(2,2,2-trifluoroethyl)-1H-1,4-diazepin-6-yl]- (CA INDEX NAME)




RN 784155-29-9 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-N-[hexahydro-7-oxo-1-(2,2,2-trifluoroethyl)-1H-1,4-diazepin-6-yl]- (CA INDEX NAME)



RN 784155-30-2 CAPLUS


CN 1H-1,4-Diazepine-1-carboxylic acid, 6-[[[4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-1-piperidinyl]carbonyl]amino]hexahydro-5-oxo-4-(2,2,2-trifluoroethyl)-, phenylmethyl ester (CA INDEX NAME)



RN 784156-98-5 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-1-[2-(methylthio)ethyl]-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 784156-99-6 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-1-(2-methoxyethyl)-2-oxo-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 784157-00-2 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-2-oxo-1-(2,2,2-trifluoroethyl)-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 784157-01-3 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-2-oxo-1-(2-pyridinylmethyl)-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●x HCl

RN 784157-02-4 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-6-(2,3-difluorophenyl)hexahydro-2-oxo-1-(4-pyridinyl)-1H-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●x HCl

L5 ANSWER 18 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2004:902106 CAPLUS Full-text
 DN 141:379810
 TI Preparation of piperidine derivatives as CGRP receptor antagonists
 IN Burgey, Christopher S.; Paone, Daniel V.; Shaw, Anthony W.; Williams, Theresa M.
 PA Merck & Co., Inc., USA
 SO PCT Int. Appl., 120 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004091514	A2	20041028	WO 2004-US11254	20040409
	WO 2004091514	A3	20050915		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004229518	A1	20041028	AU 2004-229518	20040409
	CA 2522024	A1	20041028	CA 2004-2522024	20040409
	EP 1615914	A2	20060118	EP 2004-750028	20040409
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	CN 1802369	A	20060712	CN 2004-80016114	20040409
	JP 2007525450	T	20070906	JP 2006-509941	20040409
	US 2006194783	A1	20060831	US 2005-551830	20051003
	US 7205292	B2	20070417		
	IN 2005DN04616	A	20070928	IN 2005-DN4616	20051010
PRAI	US 2003-464109P	P	20030415		
	WO 2004-US11254	W	20040409		
OS	MARPAT 141:379810				
GI					

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. I [A = a bond, C(R2)2, O, S(O)m, or NR2; B = (C(R2)2)n; m = 0-2; n = 0 or 1; R1 = H, alkyl, alkenyl, alkynyl, cycloalkyl, (substituted)heterocyclyl, (hetero)aryl; R2 = H, alkyl, alkenyl, alkynyl, cycloalkyl, (substituted)heterocyclyl, (hetero)aryl; R3 = H, (substituted)alkyl, F, CN, CO2R4; R4 = H, (fluoro)alkyl, cycloalkyl, (hetero)aryl, (substituted)benzyl; G-J = N, NC(R5)2, C:CR5, C:N, CR5, etc.; R5 = H, (substituted)alkyl, CN, OR4, N(R4)2, CO2R4; R6 = H, (cyclo)alkyl, (substituted)(hetero)aryl, etc.; W = O, NR4, C(R4)2; X = C or S; Y = O, (R4)2, NCN, NSO2Me, NCONH2, or Y = O2 when X = S] were prepared as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. For example, compound II was prepared via acylation of (3R,7R)-3-amino-1-(cyclopropylmethyl)-7-phenylazepan-2-one (preparation given) and 4-nitrophenyl

chloroformate and subsequent reaction with 4-(2-oxo-1,4-dihydroquinazolin-3-(2H)-yl)piperidinium chloride (preparation given). Compds. of the present invention had activity as antagonists of the CGRP receptor, as determined by described assays, with K_i or IC_{50} values of generally less than 50 μM .


IT 783368-03-6P 783368-04-7P 783368-05-8P
783368-06-9P 783368-07-0P 783368-57-0P
783368-58-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(claimed compound; preparation of piperidine derivs. as CGRP receptor antagonists)

RN 783368-03-6 CAPLUS


CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[hexahydro-2-oxo-1-(phenylmethyl)-1H-azepin-3-yl]- (CA INDEX NAME)



RN 783368-04-7 CAPLUS

CN 1H-Azepine-1-acetic acid, 3-[[[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]carbonyl]amino]hexahydro-2-oxo-7-phenyl-, 1,1-dimethylethyl ester, (3R,7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 783368-05-8 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[(3S)-hexahydro-2-oxo-1-(phenylmethyl)-1H-azepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 783368-06-9 CAPLUS

CN 1H-Azepine-1-acetic acid, 3-[[[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]carbonyl]amino]hexahydro-2-oxo-7-phenyl-, 1,1-dimethylethyl ester, (3S,7S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 783368-07-0 CAPLUS


CN 1-Piperidinecarboxamide, N-[(3S,7S)-1-(cyclopropylmethyl)hexahydro-2-oxo-7-phenyl-1H-azepin-3-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 783368-57-0 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(2S,6R)-4-(cyclopropylmethyl)hexahydro-5-oxo-2-phenyl-1,4-oxazepin-6-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 783368-58-1 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(2R,6R)-4-(cyclopropylmethyl)hexahydro-5-oxo-2-phenyl-1,4-oxazepin-6-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (CA INDEX NAME)

Absolute stereochemistry.



IT 783367-79-3P 783367-80-6P 783367-81-7P
 783367-82-8P 783367-83-9P 783367-84-0P
 783367-85-1P 783367-86-2P 783367-87-3P
 783367-88-4P 783367-89-5P 783367-90-8P
 783367-91-9P 783367-92-0P 783367-93-1P
 783367-94-2P 783367-95-3P 783367-96-4P
 783367-97-5P 783367-98-6P 783367-99-7P
 783368-00-3P 783368-01-4P 783368-02-5P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of piperidine derivs. as CGRP receptor antagonists)

RN 783367-79-3 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(3R,7R)-1-(cyclopropylmethyl)hexahydro-2-oxo-7-

phenyl-1H-azepin-3-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (CA
INDEX NAME)


Absolute stereochemistry.



RN 783367-80-6 CAPLUS

CN 1H-Azepine-1-acetic acid, 3-[[[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]carbonyl]amino]hexahydro-2-oxo-7-phenyl-, 1,1-dimethylethyl ester, (3R,7R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 783367-81-7 CAPLUS

CN 1H-Azepine-1-acetic acid, hexahydro-2-oxo-7-phenyl-3-[[[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (3R,7R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 783367-82-8 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-1-(cyclopropylmethyl)hexahydro-2-oxo-6-phenyl-1H-azepin-3-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 783367-83-9 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6R)-1-(cyclopropylmethyl)hexahydro-2-oxo-6-phenyl-1H-azepin-3-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 783367-84-0 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6R)-1-(cyclopropylmethyl)hexahydro-2-oxo-6-phenyl-1H-azepin-3-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 783367-85-1 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6S)-1-(cyclopropylmethyl)hexahydro-2-oxo-6-phenyl-1H-azepin-3-yl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 783367-86-2 CAPLUS

CN 1-Piperidinecarboxamide, 4-(4-chloro-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-[(3R,6S)-hexahydro-1-(2-methoxyethyl)-2-oxo-6-phenyl-1H-azepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 783367-87-3 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-4-methyl-2-oxo-1H-benzimidazol-1-yl)-N-[(3R,6S)-hexahydro-1-(2-methoxyethyl)-2-oxo-6-phenyl-1H-azepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 783367-88-4 CAPLUS

CN 1-Piperidinecarboxamide, N-[(2S,6R)-4-(cyclopropylmethyl)hexahydro-5-oxo-2-phenyl-1,4-oxazepin-6-yl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 783367-89-5 CAPLUS

CN 1-Piperidinecarboxamide, N-[(2S,6R)-4-(cyclopropylmethyl)hexahydro-5-oxo-2-phenyl-1,4-oxazepin-6-yl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 783367-90-8 CAPLUS

CN 1-Piperidinecarboxamide, N-[(2S,6R)-4-(cyclopropylmethyl)hexahydro-5-oxo-2-phenyl-1,4-oxazepin-6-yl]-4-(6-fluoro-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 783367-91-9 CAPLUS

CN 1-Piperidinecarboxamide, N-[(2S,6R)-4-(cyclopropylmethyl)hexahydro-5-oxo-2-phenyl-1,4-oxazepin-6-yl]-4-(1,2-dihydro-2-oxo-3-quinolinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 783367-92-0 CAPLUS

CN 1-Piperidinecarboxamide, N-[(2R,6S)-4-(cyclopropylmethyl)hexahydro-5-oxo-2-phenyl-1,4-oxazepin-6-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 783367-93-1 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R,6R)-1-(cyclopropylmethyl)hexahydro-7-oxo-3-phenyl-1H-1,4-diazepin-6-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 783367-94-2 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R)-1-(cyclopropylmethyl)hexahydro-2-oxo-1H-azepin-3-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 783367-95-3 CAPLUS


CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[(3R)-hexahydro-2-oxo-1-(phenylmethyl)-1H-azepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 783367-96-4 CAPLUS

CN 1-Piperidinecarboxamide, N-[hexahydro-2-oxo-1-(phenylmethyl)-1H-azepin-3-yl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)- (CA INDEX NAME)




RN 783367-97-5 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[(3R)-1-(cyclopropylmethyl)hexahydro-2-oxo-1H-azepin-3-yl]- (CA INDEX NAME)

hexahydro-1-[(4-hydroxyphenyl)methyl]-2-oxo-1H-azepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 783367-98-6 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[(3R)-hexahydro-1-[(3-methoxyphenyl)methyl]-2-oxo-1H-azepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 783367-99-7 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[(3R)-hexahydro-1-[(3-hydroxyphenyl)methyl]-2-oxo-1H-azepin-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 783368-00-3 CAPLUS


CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[hexahydro-3-[(4-hydroxyphenyl)methyl]-2-oxo-1-(phenylmethyl)-1H-azepin-3-

yl]- (CA INDEX NAME)



RN 783368-01-4 CAPLUS


CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-[hexahydro-3-[(4-methoxyphenyl)methyl]-2-oxo-1H-azepin-3-yl]- (CA INDEX NAME)



RN 783368-02-5 CAPLUS

CN 1-Piperidinecarboxamide, N-[(2R,6R)-4-(cyclopropylmethyl)hexahydro-5-oxo-2-phenyl-1,4-oxazepin-6-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.




IT 783368-38-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of piperidine derivs. as CGRP receptor antagonists)

RN 783368-38-7 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[hexahydro-2-oxo-3-[[4-(phenylmethoxy)phenyl]methyl]-1-(phenylmethyl)-1H-azepin-3-yl]- (CA INDEX NAME)



```
=> d l2; d his; log y
L2 HAS NO ANSWERS
L1 STR
```



```
G1 C,O,S,N
G2 C,O,N
G3 C,S
G4 C,N
```

Structure attributes must be viewed using STN Express query preparation.
L2 QUE ABB=ON PLU=ON L1

(FILE 'HOME' ENTERED AT 14:02:56 ON 28 MAR 2008)

FILE 'REGISTRY' ENTERED AT 14:03:12 ON 28 MAR 2008

```
L1 STRUCTURE UPLOADED
L2 QUE L1
L3 24 S L2
L4 492 S L2 FUL
```

FILE 'CAPLUS' ENTERED AT 14:03:43 ON 28 MAR 2008

```
L5 18 S L4
```

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	100.02	278.59
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-14.40	-14.40

STN INTERNATIONAL LOGOFF AT 14:06:18 ON 28 MAR 2008